KINDAI UNIVERSITY


*A space between the first name and last name, please enter

HOSOMI Kouichi

Profile

FacultyDepartment of Pharmacy / Graduate School of Medicine
PositionAssociate Professor
Degree
Commentator Guidehttps://www.kindai.ac.jp/meikan/807-hosomi-kouichi.html
URL
Mail
Last Updated :2020/09/30

Research Activities

Research Areas

  • Life sciences, Clinical pharmacy

Published Papers

  • Influence of co-initiation of antiulcer drugs on persistence and adherence to low-dose aspirin: A retrospective cohort study using a Japanese claims database, Makiko Iwasawa, Keiko Sagami, Satoshi Yokoyama, Kouichi Hosomi, Mitsutaka Takada, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 58(4), 214 - 222, Apr. 2020 , Refereed
    Summary:Objective: The purpose of this study was to examine whether co-initiation of antiulcer drugs (AUDs) and low-dose aspirin (LDA) therapy is beneficial for good adherence to LDA therapy. Materials and methods: A retrospective cohort study was conducted using the JMDC claims database. Patients for whom LDA therapy was newly initiated between January 2005 and April 2016 were selected from the JMDC database. The selected patients were divided into LDA and LDA+AUD groups and were followed up from the first prescription of LDA or LDA+AUD until the earliest of the following events: discontinuation or the end of the observation period. Unadjusted and multivariable Cox proportional hazards models controlling for all demographic and clinical characteristics were applied to examine whether the addition of an AUD to LDA improved adherence. A 1 : 1 propensity score matching analysis was conducted to balance confounders between the two groups. Results: After the propensity score matching analysis, 4,089 patients were matched in each therapy group. The Kaplan-Meier curves for the rate of LDA continuation showed a sharp decline just after the initiation of LDA therapy. A significant difference was observed in the incidence of LDA therapy discontinuation between the LDA+AUD and LDA groups (HR: 0.87, 95% CI: 0.82 - 0.92), and the median duration of LDA therapy in the LDA+AUD and LDA groups were 18 and 11 months (log-rank test: p < 0.0001), respectively. Conclusion: The therapy persistence rate in the LDA+AUD group was significantly higher than that in the LDA group.
  • Comparison of the Perception between Pharmacy Students and Practicing Pharmacists in the Acquisition of Physical Assessment Skills, Toru Otori, 37(2), 127 - 133, Dec. 2018 , Refereed
  • Association of Antipsychotic Use with Extrapyramidal Symptoms: Data Mining of the Japanese National Insurance Claims Database, Hosomi Kouichi, Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 42(2), 87 - 97, Feb. 2016
    Summary:Atypical antipsychotics are less likely to cause extrapyramidal symptoms (EPS) compared to typical antipsychotics. However, recent studies have suggested that both atypicals and typicals produce a similar risk for EPS. We performed data mining using the Japanese national insurance claims database (NDB) constructed by the Ministry of Health, Labour and Welfare in Japan. Sequence symmetry analysis was performed to identify the risk of EPS after antipsychotic use. In this study, antiparkinsonian drugs with anticholinergic action were used as a marker of EPS. Antipsychotics in combination with antiparkinsonians was examined by prescription sequence symmetry analysis (PSSA). Likewise, event sequence symmetry analysis (ESSA) was undertaken to evaluate the association between antipsychotics and EPS diagnosis. Adjusted sequence ratios (ASRs) with 95% confidence intervals (CI) were calculated. In PSSA, significant associations with antiparkinsonians were found for the whole class of antipsychotics and atypicals with ASRs of 4.82 (95%CI 4.74-4.91) and 2.97 (2.93-3.01), respectively. A significant association between typicals and antiparkinsonians was not found. In ESSA, significant associations with EPS were found for the whole class of antipsychotics and atypicals with ASRs of 1.67 (1.65-1.69) and 1.49 (1.47-1.50), respectively. A significant association between typicals and EPS was not found. The number of patients who were prescribed atypicals first was 1.5 times larger than the number of patients who had typicals initially prescribed. Analysis of NDB demonstrated that antipsychotics increase the risk of EPS. Significant associations between EPS and atypicals (but not typicals) were found. This finding may be attributed to the prescribing sequence of antipsychotics.
  • Association between Antipsychotic Use and Extrapyramidal Symptoms::Data Mining of the FDA Adverse Event Reporting System and the Japanese Adverse Drug Event Report Database, Hosomi Kouichi, Park Binawool, Inose Ryo, Fujimoto Mai, Takada Mitsutaka, Iyakuhin Johogaku, Iyakuhin Johogaku, 17(3), 125 - 132, Nov. 2015
    Summary:Objective: To examine the association between atypical and typical antipsychotics and extrapyramidal symptoms (EPS), we analyzed the US Food and Drug Administration Adverse Event Reporting System (FAERS) and the Japanese Adverse Drug Event Report database (JADER) from the Pharmaceuticals and Medical Devices Agency (PMDA).
    Methods: A reporting odds ratio was calculated and used to detect spontaneous report signals, with detection defined as a lower limit >1 in a 95% confidence interval.  In addition, time to onset and age at onset of EPS were investigated.
    Results: Drug-reaction pairs were identified in both FAERS (n=29,017,485) and JADER (n=2,079,653).  In analyses of both databases, significant associations were found between atypical and typical antipsychotics and EPS.  Atypical antipsychotics cause EPS with a longer duration of therapy compared to typical ones.  EPS in patients treated with atypical antipsychotics was observed at a broad range of ages compared to the patients treated with typical ones.
    Conclusion: Atypical antipsychotics, like typical ones, may increase the risk of EPS.  Because of the longer latency of onset, it may be difficult to find EPS associated with atypical antipsychotics.  Therefore, the severe symptom may be developed in patients treated with atypical antipsychotics.  The attention should be paid to the EPS in patients of all ages treated with atypical antipsychotics.
  • Applied Data Mining of the FDA Adverse Event Reporting System, FAERS, and the Japanese Adverse Drug Event Report Database, JADER: Signal Detection of Adverse Events by New Quinolones, Hosomi Kouichi, Arai Mari, Fujimoto Mai, Takada Mitsutaka, Iyakuhin Johogaku, Iyakuhin Johogaku, 17(1), 15 - 20, May 2015
    Summary:Objective: Signal detection by analyzing adverse event spontaneous report databases is used to monitor drug safety.  One of the major spontaneous report databases is the FDA Adverse Event Reporting System (FAERS).  Recently, the Japanese Adverse Drug Event Report database (JADER) was released.  To compare FAERS and JADER, we calculated the signals of adverse events by new quinolones (NQs).
    Methods: We extracted reports of adverse events by NQs from FAERS and JADER, and analyzed them using the ROR data mining algorithm.  Thirteen kinds of NQs were extracted, and the terms of adverse events extracted were defined by MedDRA.
    Results: There were 35,990,645 reports in FAERS and 1,643,404 reports in JADER.  Significant RORs were found for hypersensitivity (FAERS: 1.78, JADER: 1.47), arrhythmia (1.07, 0.68), hypoglycemia (1.80, 2.03), hyperglycemia (0.72, 0.78), rhabdomyolysis (1.01, 0.78), tendon disorders (15.18, 6.59), psychiatric symptoms (1.12, 0.45) and convulsion (0.99, 1.31).  We identified 4 types of adverse events by comparing FAERS and JADER: 1) Signal detection in both, 2) No signal detection in either, 3) Signal detection only in FAERS, 4) Signal detection only in JADER.
    Conclusion: Analyzing spontaneous report databases has several limitations, but is still a valuable tool for identifying potential associations between drugs and adverse events.  Spontaneous report databases may also be useful for detecting differences in adverse events between different races, countries and regions.
  • Signal Detection of Serious Infections Following Treatment with Biologics for Rheumatoid Arthritis::Data Mining of the FDA Adverse Event Reporting System and Japanese Adverse Drug Event Report Databases, Inose Ryo, Hosomi Kouichi, Park Binawool, Fujimoto Mai, Takada Mitsutaka, Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 40(10), 586 - 594, Oct. 2014
    Summary:To examine the association between biologics for rheumatoid arthritis and serious infections (hepatitis B, hepatitis C, tuberculosis, pneumonia and sepsis), we analyzed the US Food and Drug Administration Adverse Event Reporting System (FAERS) and the Japanese Adverse Drug Event Report database (JADER) of Pharmaceuticals and Medical Devices Agency (PMDA). The reporting odds ratio was calculated and used to detect spontaneous report signals, with detection defined as a lower limit >1 in a 95% confidence interval. In addition, time to onset and age at onset of tuberculosis were investigated. Drug-reaction pairs were identified in both FAERS (n = 29,017,485) and JADER (n = 2,079,653). In both databases, significant associations were observed between biologics and infections (hepatitis B, tuberculosis, pneumonia and sepsis). JADER data revealed a significant association of etanercept with hepatitis C. In FAERS, the majority of tuberculosis events, associated with all drugs, were observed within 1 month of administration, whereas most tuberculosis infections associated with biologics were observed during the 5 months following administration. In JADER, most cases of tuberculosis associated with all drugs and with biologics, respectively, were observed during the 2 months after administration. In conclusion, hepatitis C associated with etanercept treatment should be closely monitored in clinical practice. In addition, tuberculosis associated with biologics should be carefully monitored for 5 months following drug administration. Further studies are needed to confirm these findings.
  • The Association between Statin Use and the Risk of Sleep Disturbances: Data Mining of Claims Database, Fujimoto Mai, Takamoto Masashi, Hosomi Kouichi, Takada Mitsutaka, Iyakuhin Johogaku, Iyakuhin Johogaku, 16(2), 53 - 62, Aug. 2014
    Summary:Objective: To examine the association between statin use and the risk of sleep disturbances, data mining was performed on a claims database.
    Methods: Symmetry analysis was carried out to identify the risk of sleep disturbances after statin use during the period from January 2005 to December 2011.  Statin use in combination with hypnotic drugs was examined by prescription sequence symmetry analysis.  In this study, hypnotic drugs that are commonly prescribed for the treatment of insomnia were used as markers of sleep disturbances produced by statins. Likewise, event sequence symmetry analysis was undertaken to evaluate the association between statin use and the diagnosis of sleep disturbances.
    Results: Significant associations of statin use with short-acting hypnotic drugs were found, with an adjusted SR (sequence ratio) of 1.23 (95%CI: 1.04-1.45) at an interval of 12 months.  Otherwise, significant associations between individual statin use and hypnotic drug use were not found.  Significant associations between use of statins and the diagnosis of sleep disturbances were not also found in this study.
    Conclusions: Analysis of the claim database demonstrated that statin therapy might be associated with an emergence of sleep disturbances.  Therefore, individuals prescribed statins should be considered as having an increased risk of sleep disturbances.
  • Signal Detection of hepatitis B and hepatitis C by molecularly-targeted drugs for cancer::Data Mining of FDA Adverse Event Reporting System and Japanese Adverse Drug Event Report database, Inose Ryo, Hosomi Kouichi, Park Binawool, Fujimoto Mai, Takada Mitsutaka, Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 40(5), 268 - 277, May 2014
    Summary:Several case reports of hepatitis B virus reactivation after rituximab administration have been documented. We investigated the association between hepatitis B and C and 15 kinds of molecular-targeted drugs for cancer. We compared two databases, the Food and Drug Administration Adverse Event Reporting System (FAERS) and the Japanese Adverse Drug Event Report database (JADER) of the Pharmaceuticals and Medical Devices Agency (PMDA). Quantitative analysis involved calculating the reporting odds ratio (ROR) and 95% confidence interval (95% CI) as a measure of disproportionality. ROR is a tool that detects signals of adverse events for individual drugs, with signals detected when the lower limit of the 95% CI of ROR is > 1. We also investigated the timing of the adverse events and the age of the patients. There were 29,017,485 reports in FAERS and 2,079,653 reports in JADER. Signals were detected for rituximab-associated hepatitis B and hepatitis C, trastuzumab-associated hepatitis B, and imatinib-associated hepatitis B. In FAERS, hepatitis B often occurred within 1 month, whereas rituximab-associated hepatitis B often occurred 2-6 months after administration. In JADER, hepatitis B and rituximab-associated hepatitis B often occurred 1-3 months after administration. We conclude that signals of rituximab-associated hepatitis B and hepatitis C, trastuzumab-associated hepatitis B, and imatinib-associated hepatitis B are marked. Analyzing the timing and age of the patient at the occurrence of adverse events may suggest a relationship between drugs and these events.
  • Gastrointestinal tract injury Associated with Aspirin and Other Drugs: Data Mining of the FDA Adverse Event Reporting System, FAERS, Hosomi Kouichi, Fujimoto Mai, Hachiken Hiroko, Sumitoko Keita, Takada Mitsutaka, Iyakuhin Johogaku, Iyakuhin Johogaku, 15(4), 147 - 154, Feb. 2014
    Summary:Objective: To examine the signal of gastrointestinal tract injury induced by aspirin and other drugs, we analyzed the US FDA Adverse Event Reporting System (FAERS).
    Methods: After deleting duplicate submissions, we analyzed the reports involving gastrointestinal tract injury associated with aspirin, H2-receptor antagonists (H2RAs), proton pump inhibitors (PPIs), ACE inhibitors, angiotensin II receptor blockers (ARBs), and antiplatelet and antithrombotic drugs.  The reporting odds ratio (ROR), a recognized pharmacovigilance tool, was used for the quantitative detection of signals.
    Results: Based on 29,017,485 co-occurrences, i.e., drug-adverse event pairs, found in 1,645,605 reports from 2004 to 2009, the ROR-associated gastrointestinal tract injury for aspirin alone, aspirin with H2RAs, aspirin with PPIs, aspirin with ACE inhibitors, aspirin with ARBs, and aspirin with antiplatelet and antithrombotic drugs were 2.88, 1.42, 1.46, 1.00, 1.05, and 2.98-8.26, respectively.  The following summarizes the types of listed reports: 86 reports described the daily aspirin doses, and 36/86 were between 75 and 100 mg; 343 reports described the periods between the start-date for aspirin and the date when gastrointestinal tract injury occurred, of which 128/343 were within one month while 215/343 were over one month; additionally, 78 reports described the total cumulative doses of aspirin, and 17/78 were between 1 and 5 g.
    Conclusion: The data suggest that H2RAs, PPIs, ACE inhibitors, and ARBs may reduce gastrointestinal tract injury associated with aspirin in possibility.
  • The improvement item extracted by Customer Satisfaction (CS) analysis Evaluation on the Long-term pharmacy practice of 6 year-pharmacy students by Customer Satisfaction Analysis (CS Analysis), 大鳥徹, 村上悦子, 北小路学, 細見光一, 井上知美, 小竹武, 高田充隆, 松山賢治, J Pharm Commun, J Pharm Commun, 9(1), 17 - 26, Nov. 2011
    Summary:薬学教育モデル・コアカリキュラムに沿った実習の実施状況を検証し、6年制長実務実習の問題点の検討と改善を目的に学生アンケートを実施した。アンケート結果は、薬学教育において改善項目の抽出などに使用されている顧客満足度(CS)分析より検討した。病院実務実習の実習内容は、「TDMについての演習あるいは実習を受けましたか?」が「要改善項目」として抽出され、薬局実務実習の実習内容は、「薬品管理に関する説明を受けましたか?」が「要改善項目」として抽出された。また、実務実習の指導にあたる指導薬剤師に関しては病院薬局共に、「指導薬剤師の言動に不快だと感じたことがありましたか?」が「改善検討項目」として抽出された。言動は実務実習を円滑に遂行する上で非常に重要かつ基本的な問題で、大学教員と実習指導薬剤師がワークショップなどで共にコミュニケーションとは何かを学び、スキルを検討する必要があった。
  • Survey on Practical Training in Community Pharmacies and Hospital Pharmacies, HOSOMI Kouichi, MUROI Nobuyuki, AZUMA Kazuo, IKEDA Rikiko, UOMOTO Michiko, OHKAWA Kyoko, MIYAKE Keiichi, NAKAGAWA Motoko, KAWAMOTO Yukiko, KIYOHARA Yoshifumi, KIM Ke-Ih, SAWASAKI Takashi, ONO Tatsuya, NISHIDA Hideyuki, OHNO Mariko, OGATA Sonoko, FUKUSHIMA Shoji, TOKUYAMA Shogo, OHNISHI Noriaki, HIRAI Midori, MATSUYAMA Kenji, Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 32(1), 64 - 72, Jan. 2006
    Summary:We conducted a survey on the practical training of pharmacy students in 47 community pharmacies and 76 hospital pharmacies in Hyogo Prefecture. Items surveyed included the acceptance system for pharmacy students, practical training curriculum, problems and difficulties. In many community pharmacies and hospital pharmacies, instruction in practical training was recognized as worthwhile despite the workload involved. Though the content of the practical training varied, dispensing and medication instruction were the most common items in the practical training for both community pharmacies and hospital pharmacies. Communication with patients and management of medication history were the focus of training in community pharmacies, while the major aspects of training in hospital pharmacies were dispensing of injections and TDM (therapeutic drug monitoring).
    Many pharmacists were of the opinion that the content and goals of the training should be reviewed and that it needed to be further evaluated. Revision of the practical training in universities was also recommended. Further, in order to achieve an efficient practical training curriculum it was felt that the training should be more linked to the special characteristics of community pharmacies and hospital pharmacies.
  • Clinical Efficacy of Shitei-decoction for Hiccups, HOSOMI Kouichi, KUBO Yoshiyasu, OKUNO Akihiro, UMETANI Yoshiharu, HASHIMOTO Masaru, ARAYA Teruhisa, KOMORI Hideshi, HIRAI Midori, MATSUYAMA Kenji, Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 31(3), 228 - 232, Mar. 10 2005
    Summary:We examined the clinical efficacy of shitei-decoction in 108 patients with hiccups with respect to various factors influencing them : sex, age, other drugs for hiccups, use of benzodiazepines, malignant tumors, use of antitumor agents, metastasis, complications and stress. Hiccups completely disappeared in 63 of the 108 patients following the administration of shitei-decoction, a rate of 58.3%. However, if we judge efficacy by the sum of patients whose hiccups disappeared and those who experienced remission, the efficacy rate for shitei-decoction was 82.4%. The chi-square test showed that there was no significant correlation between the above hiccup influencing factors and the efficacy of shitei-decoction. Despite previous reports to the contrary, there was no correlation between the efficacy of shitei-decoction and co-administration of benzodiazepines. However, the efficacy of shitei-decoction tended to be higher in patients with brain metastasis, suggesting that efficacy may be greater for central hiccups than peripheral hiccups.
  • Usefulness of Questions from Patients and Their Families in Medication Guidance : Role of the Pharmacist in Integrated Therapy for Blood Cancer, OKUNO Akihiro, HOSOMI Kouichi, MAEKAWA Megumi, UMETANI Yoshiharu, TSUDA Yasuo, OHNISHI Shinsaku, ARAYA Teruhisa, YAMAMOTO Kinya, TAKAMIYA Shizuo, SATO Michiaki, MATSUYAMA Kenji, Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 30(10), 656 - 665, Oct. 10 2004
    Summary:This report describes how good medication guidance may be provided to patients with blood cancer and discusses the role of the pharmacist in raising the satisfaction of patients and family members with treatment. Chemotherapy for blood cancer causes a variety of severe adverse reactions, giving patients and their families a feeling of anxiety towards it. It is therefore necessary for pharmacists to provide medication guidance in order to reduce anxiety towards drugs during long-term chemotherapy.
    In the present study, we examined questions regarding chemotherapy from patients and their families for 32 cases in the past 3 years. The 485 questions asked were classified according to subject as follows : 1) Adverse reactions-40%, 2) Chemotherapy protocol-12%, 3) Blood transfusions-7%, 4) Effects of chemotherapy-6%, 5) Granulocyte-colony stimulating factor (G-CSF) -6%, 6) Method of use-4%, 7) Drugs preventing opportunistic infections-4%, 8) Administration method-3%, 9) Chemotherapy in outpatient ward-3 %, 10) High-dose chemotherapy-3 %, 11) Discharge and short stay at home-1%, 12) Drop-out-1 %, 13) Drawing blood-1 %, 14) Color of chemotherapy agents for injection-1%, and 15) Differences between treatment strategies at other hospitals-1%.
  • Association Between Antipsychotics and Osteoporosis Based on Real-World Data, Satoshi Yokoyama, Shoki Wakamoto, Yuki Tanaka, Chihiro Nakagawa, Kouichi Hosomi, Mitsutaka Takada, ANNALS OF PHARMACOTHERAPY, ANNALS OF PHARMACOTHERAPY, 54(10), 988 - 995, Oct. 2020 , Refereed
    Summary:Background: Osteoporosis, which is a major public health concern, has been known to reduce health-related quality of life. Some studies have suggested that antipsychotics could perhaps cause osteoporosis by increasing serum prolactin levels. However, the association between antipsychotics and the risk for developing osteoporosis has been controversial. Objective: The present study aimed to assess the association between antipsychotic use and onset of osteoporosis in real-world settings. Methods: A multimethod data-mining approach using different algorithms and databases was used. First, disproportionality analysis was conducted using the US Food and Drug Administration Adverse Event Reporting System (FAERS) database (2004-2017) with reporting odds ratio (ROR) and information component (IC) being used to indicate a signal. Furthermore, a sequence symmetry analysis using data from a large Japanese administrative claims database (2005-2017; JMDC Inc, Japan) was conducted. Short-term intervals (ie, 12, 24, and 36 months) were set to investigate the association between antipsychotic use and onset of osteoporosis using the adjusted sequence ratio (SR) to indicate a signal. Results: No potential association between osteoporosis and all antipsychotics was observed in the FAERS database, except for perphenazine, which exhibited significant signals using both ROR and IC. Moreover, no potential association between osteoporosis and antipsychotics was observed in the JMDC claims database, except for sulpiride and aripiprazole. None of the antipsychotics indicated significant signals using all analyzed items (ROR, IC, and adjusted SR). Conclusion and Relevance: Real-world data show no association between antipsychotic use and the onset of osteoporosis. Further pharmacoepidemiological studies are needed for causality assessment.
  • Polypharmacy in three different spontaneous adverse drug event databases ., Takayuki Mabuchi, Kouichi Hosomi, Satoshi Yokoyama, Mitsutaka Takada, International journal of clinical pharmacology and therapeutics, International journal of clinical pharmacology and therapeutics, Jul. 30 2020 , Refereed
    Summary:OBJECTIVE: Polypharmacy has become a major problem in medical care worldwide, including in Japan. The purpose of this study was to investigate the current situation of polypharmacy using different spontaneous adverse drug event report databases. MATERIALS AND METHODS: A retrospective data analysis was performed using reports from 2007 to 2015 from three different spontaneous adverse drug event report databases: the Japanese Adverse Drug Event Report (JADER) constructed by the Pharmaceuticals and Medical Devices Agency in Japan, the US Food and Drug Administration (FDA) Adverse Drug Event Reporting System (FAERS) constructed by the FDA in the United States, and the Canada Vigilance Adverse Reaction Online Database (CVARD) constructed by the government of Canada. Polypharmacy trends during the study period were investigated. RESULTS: The mean numbers of drugs per report in the JADER, FAERS, and CVARD databases during the study period were 6.62, 3.76, and 3.44, respectively. The mean number of drugs per report increased with age in all three databases, with a peak at ages 70 - 79 years in all three databases (7.0 drugs for JADER, 4.7 drugs for FAERS, and 4.2 drugs for CVARD). CONCLUSION: Adverse event reports were more likely to develop in the patients treated through polypharmacy. Polypharmacy in Japan should be improved to prevent adverse events. Additionally, the patients aged ≥ 80 years tended to develop adverse events even if the number of prescribed drugs was relatively small. Therefore, polypharmacy should be noted in these patients to prevent adverse events.
  • Relationship between serum calcium and creatinine in hematopoietic stem cell transplantation patients treated with foscarnet, Ryosuke Ota, Atsushi Hirata, Keisuke Noto, Satoshi Yokoyama, Kouichi Hosomi, Mitsutaka Takada, Hiroshi Matsuoka, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 58(5), 274 - 281, May 2020 , Refereed
    Summary:Objective: The relationship between serum creatinine and calcium (Ca) was investigated in hematopoietic stem cell transplantation (HSCT) patients treated with foscarnet. Materials and methods: A retrospective study was performed to investigate the development of foscarnet-induced renal dysfunction in patients who received HSCT from April 2010 to November 2018 at the Kindai University Nara Hospital. A total of 80 patients were identified from the medical records, and 42 patients who met the inclusion criteria were enrolled in this study. Renal dysfunction was classified according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Results: A significant inverse relationship was observed between serum creatinine and Ca levels (r = -0.372; p < 0.0001; y = -0.537x + 9.268). A separate analysis divided into renal dysfunction and non-renal dysfunction groups showed that there was a significant relationship between serum creatinine and Ca levels in the renal dysfunction group (r = -0.531: p < 0.0001; y = -0.617x + 9.239) but not in the non-renal dysfunction group (r = -0.011; p = 0.561; y = -0.023x + 8.934). The optimal cutoff for the minimum Ca level was calculated to be 8.1 mg/mL. Conclusion: A significant inverse relationship was observed between serum creatinine and Ca levels in HSCT patients with foscarnet-induced renal dysfunction. Foscarnet-induced renal dysfunction should be noted if Ca levels fall below 8.1 mg/dL. Monitoring Ca levels may be useful for detecting renal dysfunction at early stages in patients treated with foscarnet.
  • Association between malignancy and methotrexate and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, Ryo Inose, Natsue Hashimoto, Kouichi Hosomi, Satoshi Yokoyama, Mitsutaka Takada, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 58(3), 131 - 138, Mar. 2020 , Refereed
    Summary:Objective: This study was aimed at investigating the risk of malignancies in rheumatoid arthritis patients treated with methotrexate (MTX), and whether the addition of biological disease-modifying antirheumatic drugs (bDMARDs) further increases the risk of malignancies in patients receiving MTX therapy, by using data from a spontaneous adverse reaction database. Materials: Patient data from the U.S. Food and Drug Administration's Adverse Event Reporting System (FAERS) from the first quarter of 2004 to the end of 2015 were analyzed. Methods: A data subset analysis was performed to investigate whether the use of bDMARDs further increased the risk of malignancies in patients receiving MTX therapy. Results: MTX showed significant associations with all malignancies except liver cancer. bDMARDs showed significant associations with stomach cancer, colorectal cancer, prostate cancer, ovarian cancer, malignant melanoma, and lung cancer. In addition, bDMARD use increased the risk of breast, ovarian, and lung cancers in rheumatoid arthritis patients receiving MTX therapy. Conclusion: MTX use was significantly associated with various malignancies. Moreover, concomitant use of bDMARDs further increased the risk of breast, ovarian, and lung cancers in MTX-treated patients with rheumatoid arthritis.
  • Time-to-onset analysis of amiodarone-associated thyroid dysfunction, Sayoko Kinoshita, Kouichi Hosomi, Satoshi Yokoyama, Mitsutaka Takada, JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 45(1), 65 - 71, Feb. 2020 , Refereed
    Summary:What is known and objective Amiodarone (AMD) treatment is associated with a number of significant adverse effects including thyroid dysfunction. However, the relationship between the development of thyroid dysfunction and the dosage and treatment duration of AMD remains unclear. The purpose of this study was to examine the onset profiles of amiodarone-associated thyroid dysfunction using a spontaneous adverse drug reaction (ADR) reporting database. Methods Data were obtained from the US Food and Drug Administration Adverse Event Reporting System (FAERS). For signal detection of spontaneous ADRs, the reporting odds ratio (ROR) and information component (IC) were calculated. Cumulative incidences of hyperthyroidism and hypothyroidism were assessed using the Kaplan-Meier method, and time-to-onset profiles were analysed using the Weibull shape parameter (WSP) test. Results and discussion The median time-to-onset of hyperthyroidism associated with AMD and other drugs was 720.0 (range: 225.5-1145.0) and 101.5 (range: 14.0-468.8) days, respectively. Patients treated with AMD showed a significantly longer time-to-onset of hyperthyroidism than those treated with other drugs (P < .001). The median time-to-onset of hypothyroidism associated with AMD and other drugs was 183.0 (range: 35.0-727.8) and 153.0 (range: 19.0-608.0) days, respectively. There was no significant difference in the time-to-onset of hypothyroidism between patients treated with AMD and those treated with other drugs (P = .13). For hyperthyroidism, the WSP test showed that AMD had a wear-out failure-type profile and other drugs had early failure-type profiles. For hypothyroidism, the WSP test showed that both AMD and other drugs had early failure-type profiles. What is new and conclusions Amiodarone-associated hyperthyroidism had a different onset profile than hyperthyroidism associated with other drugs. Because the time-to-onset of AMD-associated hyperthyroidism is widely distributed, sustained and continuous attention is required to detect and treat hyperthyroidism during AMD treatment. In contrast, AMD-associated hypothyroidism had an onset profile that was similar to that of other drugs, suggesting that attention should be focused on the earlier stages of treatment.
  • Association between oral anticoagulants and osteoporosis: Real-world data mining using a multi-methodological approach, Satoshi Yokoyama, Shoko Ieda, Mirai Nagano, Chihiro Nakagawa, Makoto Iwase, Kouichi Hosomi, Mitsutaka Takada, INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 17(4), 471 - 479, 2020 , Refereed
    Summary:Introduction: Warfarin and direct oral anticoagulants (DOACs) have been widely used in antithrombotic therapy. Although warfarin use has been suspected to be associated with osteoporosis risk, several studies have shown otherwise. Conversely, a few reports have found an association between DOACs and osteoporosis. This study therefore clarifies the association between oral anticoagulants and osteoporosis by analyzing real-world data using different methodologies, algorithms, and databases.Methods: Real-world data from the US Food and Drug Administration Adverse Event Reporting System (FAERS; 2004-2016) and Japanese administrative claims database (2005-2017; JMDC Inc., Tokyo) were used. Reporting odds ratio (ROR) and information component (IC) were calculated through disproportionality analysis (DPA) using reports recorded in the FAERS. Sequence symmetry analysis (SSA) was employed to calculate the adjusted sequence ratio (SR) using the JMDC Claims Database. For the adjusted SR and ROR, a significant signal was detected when the lower limit of the two-sided 95% confidence interval (CI) was more than 1. For the IC, a significant signal was detected when the lower limit of the 95% CI was more than 0.Results: DPA for warfarin found significant signals for osteoporosis in ROR (1.43, 95% CI: 1.32-1.54) and IC (0.50, 95% CI: 0.39-0.61). SSA showed a significant association between warfarin use and osteoporosis or bisphosphonate use. Moreover, a significant association was observed in males and females, albeit only for warfarin.Conclusion: Multi-methodological data mining revealed that warfarin use, not DOACs, is significantly associated with osteoporosis regardless of sex difference.
  • Inverse Association between Metformin and Amiodarone-Associated Extracardiac Adverse Events, Sayoko Kinoshita, Kouichi Hosomi, Satoshi Yokoyama, Mitsutaka Takada, INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 17(3), 302 - 309, 2020 , Refereed
    Summary:Background: The association between metformin and amiodarone-induced adverse events was examined using spontaneous adverse event database. Additionally, the association between other antidiabetic drugs and amiodarone-induced adverse events were also examined.Methods: A total of 6,153,696 reports from the first quarter of 2004 through the fourth quarter of 2015 were downloaded from the US Food and Drug Administration adverse event reporting system. Reporting odds ratio (ROR) and information component (IC) were used to detect associations between antidiabetic drugs and amiodarone-associated adverse events. Additionally, subset data analysis was performed to investigate whether the use of antidiabetic drugs further increased or decreased the risk of adverse events in patients receiving amiodarone therapy. Next, the RORs were adjusted for coadministered antidiabetic drugs using logistic regression analysis.Results: By whole dataset analysis, significant inverse associations were found between metformin and interstitial lung disease (ROR 0.84, 95% confidence interval [CI] 0.79-0.90; IC -0.24, 95% CI -0.33 to -0.15). In the subset data analysis, metformin (ROR 0.62, 95%CI 0.43-0.89; IC -0.63, 95%CI -1.14 to -0.11), sulfonylureas (ROR 0.53, 95%CI 0.32-0.85; IC -0.85, 95%CI -1.53 to -0.17), and dipeptidyl peptidase-4 (DPP-4) inhibitors (ROR 0.25, 95%CI 0.08-0.78; IC -1.66, 95%CI -3.08 to -0.23) were inversely associated with hyperthyroidism. Additionally, metformin (ROR 0.43, 95%CI 0.33-0.57; IC -1.09, 95%CI -1.49 to -0.69), sulfonylureas (ROR 0.64, 95%CI 0.48-0.86; IC -0.59, 95%CI -1.00 to -0.17), and DPP-4 inhibitors (ROR 0.47, 95%CI 0.27-0.81; IC -0.99, 95%CI -1.76 to -0.22) were inversely associated with interstitial lung disease. In the logistic regression analyses, DPP-4 inhibitors (adjusted ROR 0.32, 95% CI 0.10-1.00) and metformin (adjusted ROR 0.46, 95% CI 0.34-0.62) were inversely associated with amiodarone-associated hyperthyroidism and interstitial lung disease, respectively.Conclusion: Metformin is a candidate drug to reduce the risk of amiodarone-induced hyperthyroidism and interstitial lung disease.
  • Drug interactions between tacrolimus and clotrimazole troche: a data mining approach followed by a pharmacokinetic study, Takaya Uno, Kyoichi Wada, Kouichi Hosomi, Sachi Matsuda, Megumi Morii Ikura, Hiromi Takenaka, Nobue Terakawa, Akira Oita, Satoshi Yokoyama, Atsushi Kawase, Mitsutaka Takada, EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 76(1), 117 - 125, Jan. 2020 , Refereed
    Summary:Purpose This study investigated the effects of clotrimazole troche on the risk of transplant rejection and the pharmacokinetics of tacrolimus. Methods The data mining approach was used to investigate whether the use of clotrimazole increased the risk of transplant rejection in patients receiving tacrolimus therapy. Patient data were acquired from the US Food and Drug Administration's Adverse Event Reporting System (FAERS) from the first quarter of 2004 to the end of 2017. Next, we retrospectively investigated the effect of clotrimazole troche on tacrolimus pharmacokinetics in seven patients who underwent heart transplantation between March and December 2017. Results The FAERS subset data indicated a significant association between transplant rejection and tacrolimus with clotrimazole [reporting odds ratio 1.92, 95% two-sided confidence interval (95% CI) 1.43-2.58, information component 0.81, 95% CI 0.40-1.23]. The pharmacokinetic study demonstrated a significant correlation between trough concentration (C-0) and area under the concentration-time curve of tacrolimus after discontinuation of clotrimazole (R-2 = 0.60, P < 0.05) but not before its discontinuation. Furthermore, the median clearance/bioavailability of tacrolimus after discontinuation of clotrimazole was 2.2-fold greater than that before its discontinuation (0.27 vs. 0.59 L/h/kg, P < 0.05). The median C-0 decreased from 10.7 ng/mL on the day after discontinuation of clotrimazole to 6.5 ng/mL at 1 day and 5.3 ng/mL at 2 days after its discontinuation. Conclusion Immediate dose adjustments of tacrolimus may be beneficial to avoid transplant rejection when clotrimazole troche is added or discontinued.
  • Polypharmacy in elderly patients in Japan: Analysis of Japanese real-world databases, Takayuki Mabuchi, Kouichi Hosomi, Satoshi Yokoyama, Mitsutaka Takada, JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, Jan. 2020 , Refereed
    Summary:What is known and objective Polypharmacy is associated with an increased risk of adverse drug reactions (ADRs) and drug interactions, decreased adherence to medication and increased medical cost. Recently, polypharmacy has become a major problem in medical care in Japan as a result of the increase in the ageing population. The purpose of this study was to investigate the current situation of polypharmacy and the association between polypharmacy and adverse events. Methods A retrospective data analysis was performed using two different real-world data from 2007 to 2015 in Japan. The Japanese Adverse Drug Event Report (JADER), a public spontaneous adverse drug reaction database constructed by the Pharmaceuticals and Medical Devices Agency (PMDA), and a large prescription database constructed by a database vendor (Japan Medical Information Research Institute, Inc Japan [JMIRI]) were analysed. Trends of polypharmacy during the study period were investigated. Results and discussion The mean number of drugs per report in the JADER database and per prescription in the JMIRI databases during the study period ranged from 4.8 to 5.6 and 3.5 to 3.7, respectively. The mean number of drugs increased with age in both the JADER and JMIRI databases, and the peak of the mean number of drugs was at 80-89 years (5.74 drugs) in the JADER database and at 90-99 years (4.97 drugs) in the JMIRI database. What is new and conclusions The number of drugs increased until age 90 years or more, even though adverse events are more likely to occur after the age of 80 in Japan. Therefore, polypharmacy in the elderly should be focused on the patients aged >= 80 years rather than patients aged >= 65 years from the viewpoint of the prevention of adverse events.
  • Integrative analysis of clinical and bioinformatics databases to identify anticancer properties of digoxin, Satoshi Yokoyama, Yasuhiro Sugimoto, Chihiro Nakagawa, Kouichi Hosomi, Mitsutaka Takada, SCIENTIFIC REPORTS, SCIENTIFIC REPORTS, 9(1), 16597 - 16597, Nov. 2019 , Refereed
    Summary:Cardiac glycosides, such as digoxin, inhibit Na+/K+-ATPases and cause secondary activation of Na+/Ca2+ exchangers. Preclinical investigations have suggested that digoxin may have anticancer properties. In order to clarify the functional mechanisms of digoxin in cancer, we performed an integrative analysis of clinical and bioinformatics databases. The US Food and Drug Administration Adverse Event Reporting System and the Japan Medical Data Center claims database were used as clinical databases to evaluate reporting odds ratios and adjusted sequence ratios, respectively. The BaseSpace Correlation Engine and Connectivity Map bioinformatics databases were used to investigate molecular pathways related to digoxin anticancer mechanisms. Clinical database analyses suggested an inverse association between digoxin and four cancers: gastric, colon, prostate and haematological malignancy. The bioinformatics database analysis suggested digoxin may exert an anticancer effect via peroxisome proliferator-activated receptor a and apoptotic caspase cascade pathways. Our integrative analysis revealed the possibility of digoxin as a drug repositioning candidate for cancers.
  • Relationship between the blood concentrations of tacrolimus and voriconazole in hematopoietic stem cell transplant recipients, Ryosuke Ota, Atsushi Hirata, Keisuke Noto, Satoshi Yokoyama, Kouichi Hosomi, Mitsutaka Takada, Hiroshi Matsuoka, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 57(11), 561 - 566, Nov. 2019 , Refereed
    Summary:Objective: We aimed to clarify the drug interaction between tacrolimus and voriconazole and investigate the relationship between blood concentrations of tacrolimus and voriconazole in hematopoietic stem cell transplantation (HSCT) patients. Materials and methods: A retrospective study was conducted to investigate the relationship between blood concentration of tacrolimus and that of voriconazole at the Kindai University Nara Hospital. Patients who received HSCT and tacrolimus and were prescribed voriconazole for the prevention or treatment of aspergillosis from April 2010 to July 2018 were identified from the medical records. A total of 13 patients (administration route of tacrolimus: intravenously in 6 patients. orally in 7 patients) were enrolled in the present study. Results: No significant correlation was observed between the blood concentration/dose (C/D) ratio of tacrolimus and the blood concentration of voriconazole (r = 0.38: p = 0.402; y = 102.8x + 928.1). However, a significant correlation was observed between the C/D ratio of tacrolimus and the blood concentration of voriconazole in the intravenous-administration group (r = 0.94; p = 0.0048; y = 421.9x + 810.5). Meanwhile, no significant correlation was observed in the oral-administration group (r = 0.43: p = 0.34; y = 7.9x + 719). Conclusion: The C/D ratio of tacrolimus was significantly correlated with the blood concentration of voriconazole when tacrolimus was intravenously administered. There was a difference in the mechanism of drug interaction between tacrolimus and voriconazole depending on the administration routes.
  • Clotrimazole troches can alter everolimus pharmacokinetics in post-transplant patients: A case report, Takaya Uno, Kyoichi Wada, Sachi Matsuda, Megumi Ikura, Hiromi Takenaka, Nobue Terakawa, Akira Oita, Satoshi Yokoyama, Atsushi Kawase, Kouichi Hosomi, Mitsutaka Takada, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 85(9), 2176 - 2178, Sep. 2019 , Refereed
  • Adherence to guidelines for antiulcer drug prescription in patients receiving low-dose aspirin therapy in Japan, Makiko Iwasawa, Keiko Sagami, Satoshi Yokoyama, Kouichi Hosomi, Mitsutaka Takada, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 57(4), 197 - 206, Apr. 2019 , Refereed
    Summary:Objective: Prevalence of guideline adherence for antiulcer drug prescription in patients receiving low-dose aspirin (LDA) therapy was examined and the association of risk factors with the adherence was assessed. Materials and methods: A retrospective cohort study using a population-based longitudinal healthcare database was conducted. Claims data between January 2005 and April 2016 were analyzed. A total of 3,079 patients were included in the study. The selected patients taking LDA were divided into two categories: those taking and those not taking antiulcer drugs in an inpatient setting. Additionally, they were classified into four groups according to the time antiulcer therapy was initiated. The risk factors for ulcer, such as history of gastrointestinal injuries: age >= 65 years; and concomitant use of anticoagulants, antiplatelets, oral corticosteroids, and nonsteroidal anti-inflammatory drugs except aspirin, were assessed. Results: A total of 3,079 patients were included in the study. The rate of LDA patients using antiulcer drugs was 65.2%, with the strongest single factor associated with the use of antiulcer drugs being the concomitant use of corticosteroids. Among the LDA patients not taking antiulcer drugs, 66.8% had more than one risk factor. Irrespective of the use of concomitant treatment with antiulcer drug prior to hospital admission, 78.3% of the LDA patients continued their home regimen after hospital admission. Conclusion: Our results showed that the requirement of antiulcer therapy is not routinely evaluated at hospital admission, and antiulcer drugs for patients with ulcer risks are under-prescribed. Developing strategies to screen gastrointestinal risk factors at hospital admission is required to improve the guideline adherence for LDA-induced ulcer.
  • Voriconazole trough concentration and hepatotoxicity in patients with low serum albumin, Atsushi Hirata, Keisuke Noto, Ryosuke Ota, Satoshi Yokoyama, Kouichi Hosomi, Mitsutaka Takada, Hiroshi Matsuoka, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 57(3), 135 - 143, Mar. 2019 , Refereed
    Summary:Objective: We aimed to investigate the relationship between voriconazole (VRCZ) trough concentrations and hepatotoxicity and to evaluate whether the recommended trough concentration is adequate in our clinical setting. Materials and methods: A retrospective study was performed to investigate the relationship between serum VRCZ concentrations and the development of hepatotoxicity at the Kindai University Nara Hospital. Patients treated with VRCZ from March 2010 to January 2018 were identified from the medical records. A total of 42 patients (mean age of 61.9 +/- 16.9 years; 33 males and 9 females) were enrolled in this study. Results: Hepatotoxicity developed in 28.6% (12/42) of patients treated with VRCZ, and 91.7% (11/12) of these patients developed hepatotoxicity within 3 weeks after initiating the treatment. Significantly increased aspartate aminotransferase (AST; p < 0.001), alkaline phosphatase (ALP; p < 0.001), and alanine aminotransferase (p = 0.001) levels were observed after the initiation of VRCZ therapy. In addition, significant positive correlations between AST and VRCZ trough concentrations (p = 0.017) and between ALP and VRCZ trough concentrations (p = 0.012) were observed. VRCZ trough concentration was identified as a significant independent risk factor for hepatotoxicity (adjusted odds ratio: 1.611, 95% confidence interval: 1.131 - 2.579, p = 0.006), and the cutoff serum trough concentration was calculated to be 4.2 mu g/mL. Conclusion: VRCZ-induced hepatotoxicity should be noted in the early stages of therapy. A sustained VRCZ trough concentration of similar to < 4.2 mu g/mL is recommended to prevent hepatotoxicity in patients with low serum albumin levels.
  • Risk of malignant lymphoma in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs and methotrexate, Ryo Inose, Kouichi Hosomi, Katsuyuki Takahashi, Satoshi Yokoyama, Mitsutaka Takada, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 57(2), 63 - 72, Feb. 2019 , Refereed
    Summary:Objective: This study investigated whether using biological disease-modifying antirheumatic drugs (bDMARDs) further increases the risk of malignant lymphoma in patients with rheumatoid arthritis undergoing methotrexate therapy using spontaneous adverse reaction databases in different countries. Materials and methods: Patient data were acquired from the US Food and Drug Administration's Adverse Event Reporting System (FAERS), the Japanese Adverse Drug Event Report (JADER), and the Canada Vigilance Adverse Reaction Online Database (CVARD) from the first quarter of 2004 to the end of 2015. Data subset analysis was performed to investigate whether the use of bDMARDs further increased the risk of malignant lymphoma in patients receiving methotrexate therapy. Results: The FAERS subset data indicated a significant association between Hodgkin lymphoma and methotrexate with infliximab (reporting odds ratio (ROR): 8.28. 95% CI: 5.70 - 12.02; information component (IC): 2.04, 95% CI: 1.59 - 2.49). In addition, signal scores suggested that methotrexate with infliximab (ROR: 3.26. 95% CI: 2.68 - 3.98; IC: 1.31, 95% CI: 1.04 - 1.58) was significantly associated with non-Hodgkin lymphoma (NHL). The CVARD subset data also indicated a significant association between NHL and methotrexate with infliximab (ROR: 22.82. 95% CI: 5.02 - 103.78; IC: 1.77, 95% CI: 0.13 - 3.41). However, the JADER subset data revealed no significant associations. Conclusion: The present study shows that using infliximab further increases the risk of malignant lymphoma in patients receiving methotrexate therapy.
  • Effects of clotrimazole on tacrolimus pharmacokinetics in patients with heart transplants with different CYP3A5 genotypes, Takaya Uno, Kyoichi Wada, Sachi Matsuda, Yuka Terada, Nobue Terakawa, Akira Oita, Satoshi Yokoyama, Atsushi Kawase, Kouichi Hosomi, Mitsutaka Takada, EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 75(1), 67 - 75, Jan. 2019 , Refereed
    Summary:PurposeThis study aimed to investigate the effects of clotrimazole on the pharmacokinetics of tacrolimus in Japanese patients with heart transplants with different CYP3A5 genotypes.MethodsTwenty-six patients who underwent heart transplantation between June 2012 and July 2017 were enrolled in this retrospective study. The CYP3A5 (rs776746; CYP3A5*3) genotype was determined after monitoring and analysing tacrolimus blood concentrations. The pharmacokinetic profile of tacrolimus was examined before and after the discontinuation of clotrimazole and in patients with different CYP3A5 genotypes.ResultsThe CYP3A5*1/*1, *1/*3 and *3/*3 genotypes were detected in 2, 8 and 16 patients, respectively. After clotrimazole was discontinued, the CYP3A5 expresser (CYP3A5*1/*1 or *1/*3) group had a 3.3-fold median increase in apparent oral clearance of tacrolimus (0.27 vs. 0.89L/h/kg, P=0.002) compared with the CYP3A5 non-expresser (CYP3A5*3/*3) group with a 2.2-fold median increase (0.18 vs. 0.39L/h/kg, P<0.0001). Significant correlations were observed between C-0 and area under the concentration-time curve (AUC(0-12)) of tacrolimus after the discontinuation of clotrimazole in the CYP3A5 expresser and non-expresser groups, respectively (R-2=0.49 and 0.42, all P<0.05), but not before the discontinuation of clotrimazole.ConclusionThe effects of clotrimazole on tacrolimus pharmacokinetics in the CYP3A5 expresser patients were significantly greater than those in the CYP3A5 non-expresser patients. In addition, clotrimazole disturbed the correlation between C-0 and AUC(0-12) of tacrolimus. Careful dose adjustment of tacrolimus based on CYP3A5 genotypes may be beneficial for the patients with heart transplants who are concomitantly treated with clotrimazole.
  • An integrative approach using real-world data to identify alternative therapeutic uses of existing drugs, Kouichi Hosomi, Mai Fujimoto, Kazutaka Ushio, Lili Mao, Juran Kato, Mitsutaka Takada, PLOS ONE, PLOS ONE, 13(10), e0204648, Oct. 2018 , Refereed
    Summary:Different computational approaches are employed to efficiently identify novel repositioning possibilities utilizing different sources of information and algorithms. It is critical to propose high-valued candidate-repositioning possibilities before conducting lengthy in vivo validation studies that consume significant resources. Here we report a novel multi-methodological approach to identify opportunities for drug repositioning. We performed analyses of real-world data (RWD) acquired from the United States Food and Drug Administration's Adverse Event Reporting System (FAERS) and the claims database maintained by the Japan Medical Data Center (JMDC). These analyses were followed by cross-validation through bioinformatics analyses of gene expression data. Inverse associations revealed using disproportionality analysis (DPA) and sequence symmetry analysis (SSA) were used to detect potential drug-repositioning signals. To evaluate the validity of the approach, we conducted a feasibility study to identify marketed drugs with the potential for treating inflammatory bowel disease (IBD). Primary analyses of the FAERS and JMDC claims databases identified psycholeptics such as haloperidol, diazepam, and hydroxyzine as candidates that may improve the treatment of IBD. To further investigate the mechanistic relevance between hit compounds and disease pathology, we conducted bioinformatics analyses of the associations of the gene expression profiles of these compounds with disease. We identified common biological features among genes differentially expressed with or without compound treatment as well as disease-perturbation data available from open sources, which strengthened the mechanistic rationale of our initial findings. We further identified pathways such as cytokine signaling that are influenced by these drugs. These pathways are relevant to pathologies and can serve as alternative targets of therapy. Integrative analysis of RWD such as those available from adverse-event databases, claims databases, and transcriptome analyses represent an effective approach that adds value to efficiently identifying potential novel therapeutic opportunities.
  • Bleeding Risk of Warfarin and Direct Oral Anticoagulants in Younger Population: A Historical Cohort Study Using a Japanese Claims Database, Satoshi Yokoyama, Yuki Tanaka, Kazuki Nakagita, Kouichi Hosomi, Mitsutaka Takada, INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 15(14), 1686 - 1693, 2018 , Refereed
    Summary:A historical cohort analysis of the Japan medical data center (JMDC) claims databases was performed to compare the incidence rates of bleeding events with warfarin (WF) versus direct oral anticoagulant (DOAC) treatment in patients with non-valvular atrial fibrillation. The aim of this study is to clarify the risk factors for bleeding events in younger patients newly treated with WF or DOAC in clinical practice setting. Patients who newly initiated WF or DOAC treatment from April 2012 to March 2015 were selected from the JMDC claims database. A 1:1 propensity score matching analysis was used for new users of WF or DOAC. Kaplan-Meier curves were generated to depict the time to bleeding event (total bleeding events, gastrointestinal hemorrhage, and intracranial hemorrhage) during the follow-up period. Cox proportional regression models were used to estimate the hazard ratios for total bleeding events caused by oral anticoagulants. Overall, 2,046 patients (503 WF and 1,543 DOAC) were included. After applying propensity score matching, Kaplan-Meier analysis of the WF and DOAC groups displayed comparable incidences of total bleeding events, gastrointestinal hemorrhage, and intracranial hemorrhage. Cox proportional hazards modeling showed that the use of WF was not associated with total bleeding events compared with DOAC (hazard ratio: 1.21, 95% confidence interval: 0.93-1.54, p = 0.15). This historical cohort study using a claims database indicates that the bleeding risk of DOAC was comparable to that of WF in Japanese younger population.
  • Association between Serum Amiodarone and N-Desethylamiodarone Concentrations and Development of Thyroid Dysfunction, Mikie Yamato, Kyoichi Wada, Tomohiro Hayashi, Mai Fujimoto, Kouichi Hosomi, Akira Oita, Mitsutaka Takada, CLINICAL DRUG INVESTIGATION, CLINICAL DRUG INVESTIGATION, 38(1), 39 - 48, Jan. 2018 , Refereed
    Summary:Objective This retrospective cohort study was performed to examine the association between serum amiodarone (AMD) and N-desethylamiodarone (DEA) concentrations and the development of thyroid dysfunction.Methods Patients treated with AMD from January 2012 to April 2016 were identified from the computerized hospital information system database at the National Cerebral and Cardiovascular Center. Only patients whose serum AMD and DEA concentrations had been determined at least once were included in the study.Results A total of 377 patients were enrolled. Consequently, 54 (14.3%) and 60 (15.9%) patients who developed AMD-induced thyrotoxicosis and hypothyroidism were included. The mean DEA/AMD ratio during the pre-index period in the thyrotoxicosis group (0.86 +/- 0.24) was significantly higher than in the hypothyroidism (0.68 +/- 0.27) and euthyroidism (0.78 +/- 0.30; p < 0.0001) groups. In addition, the mean DEA/AMD ratio during the post-index period in the thyrotoxicosis group (1.05 +/- 0.40) was significantly higher than in the hypothyroidism (0.81 +/- 0.24) and euthyroidism (0.88 +/- 0.22; p < 0.0001) groups. A persistently higher DEA/AMD ratio was observed throughout the study period in the thyrotoxicosis group. In addition, good correlations between the DEA/AMD ratio and the levels of free thyroxine, free triiodothyronine levels, and log (thyroid-stimulating hormone) were observed in the thyrotoxicosis and euthyroidism groups.Conclusion Patients with AMD-induced thyrotoxicosis had an increased DEA/AMD ratio and patients with AMD-induced hypothyroidism had a decreased DEA/AMD ratio before the development of thyroid dysfunction. The DEA/AMD ratio may be a predictive marker for AMD-induced thyroid dysfunction.
  • The influence of residual apixaban on bleeding complications during and after catheter ablation of atrial fibrillation, Yutaro Mukai, Kyoichi Wada, Koji Miyamoto, Kazuki Nakagita, Mai Fujimoto, Kouichi Hosomi, Takeshi Kuwahara, Mitsutaka Takada, Kengo Kusano, Akira Oita, JOURNAL OF ARRHYTHMIA, JOURNAL OF ARRHYTHMIA, 33(5), 434 - 439, Oct. 2017 , Refereed
    Summary:Background: The periprocedural protocol for atrial fibrillation (AF) ablation commonly includes anticoagulation therapy. Apixaban, a direct oral anticoagulant, is currently approved for clinical use; however, little is known about the effects of residual apixaban concentration on bleeding complications during/after AF ablation. Therefore, we measured residual apixaban concentration by using mass spectrometry and examined the anticoagulant's residual effects on bleeding complications. Methods: Fifty-eight patients (Mean age of 64.7 +/- 12.5 years; 31 males, 27 females) were enrolled and administered apixaban twice daily. We analyzed trough apixaban concentration, activated clotting time (ACT), heparin dose, and bleeding complications during/after AF ablation. Apixaban concentrations were directly measured using mass spectrometry. Results: Bleeding complications were observed in 19 patients (delayed hemostasis at the puncture site, 16; hematuria, 3; hemosputum, 1). No patient required blood transfusion. The mean trough apixaban concentration was significantly lower in patients with bleeding complications than without (152.4 +/- 73.1 vs. 206.8 +/- 98.8 ng/mL respectively, P=0.037), while the heparin dose to achieve ACT > 300 s was significantly higher in patients with bleeding complications (9368.4 +/- 2929.0 vs. 7987.2 +/- 2135.2 U/body respectively, P=0.046). Interestingly, a negative correlation was found between the trough apixaban concentration and the heparin dose to achieve ACT > 300 s (P=0.033, R=-0.281). Conclusions: Low residual plasma apixaban is associated with a higher incidence of bleeding complications during/after AF ablation, potentially because of a greater heparin requirement during AF ablation. (C) 2017 Japanese Heart Rhythm Society. Published by Elsevier B.V.
  • Response: Amiodarone-induced thyroid dysfunction and a perturbed N-desethyl-amiodarone to amiodarone ratio; could a drug-induced toxicity be regulating exposure to the offending agent?, Mitsutaka Takada, Mikie Yamato, Kyoichi Wada, Mai Fujimoto, Kouichi Hosomi, Tomohiro Hayashi, Akira Oita, EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 73(8), 1053 - 1054, Aug. 2017 , Refereed
  • Angiotensin receptor blockers and the risk of cancer: data mining of a spontaneous reporting database and a claims database, Mai Fujimoto, Migiwa Kanou, Kouichi Hosomi, Mitsutaka Takada, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 55(4), 295 - 303, Apr. 2017 , Refereed
    Summary:Objective: The aim of this study was to examine the associations between angiotensin receptor blockers (ARBs) and the risk of 10 major cancers by employing different pharmacoepidemiological assessments. Materials & methods: Data from the first quarter of 2004 through 2012 were downloaded from the US Food and Drug Administration Adverse Event Reporting System (FAERS). The reporting odds ratio (ROR) and information component (IC) were used to detect the signals. Furthermore, symmetry analysis was applied to the claims database to identify the risk of cancer after using ARBs from January 2005 to July 2013. Results: Significant inverse associations were found for all cancer types assessed as a whole (ROR: 0.78, 95% confidence interval (CI): 0.75 - 0.80; IC: -0.36, 95% CI: -0.40 to -0.31) in the analyses of FAERS database. Likewise, significant inverse association was found for all cancer types assessed as a whole (adjusted sequence ratio: 0.89, 95% CI: 0.82 - 0.96) in claims database. In addition, a significantly decreased risk for breast cancer and increased risks for pancreatic and prostate cancer were found in patients treated with ARBs in the analyses of individual cancers. Conclusions: Significant inverse association was found between ARB use and all cancer types assessed as a whole. However, in the analyses of individual cancers, the risks of ARB-induced cancer may differ according to cancer site. It may be reasonable to assume that the risks ofARB-induced cancer may differ according to cancer site.
  • Association between N-desethylamiodarone/amiodarone ratio and amiodarone-induced thyroid dysfunction, Mikie Yamato, Kyoichi Wada, Mai Fujimoto, Kouichi Hosomi, Tomohiro Hayashi, Akira Oita, Mitsutaka Takada, EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 73(3), 289 - 296, Mar. 2017 , Refereed
    Summary:We used a retrospective data mining approach to explore the association between serum amiodarone (AMD) and N-desethylamiodarone (DEA) concentrations and thyroid-related hormone levels.Laboratory data sets from January 2012 to April 2016 were extracted from the computerized hospital information system database at the National Cerebral and Cardiovascular Center (NCVC). Data sets that contained serum AMD and DEA concentrations and thyroid function tests, including thyroid-stimulating hormone (TSH), free thyroxine (FT4), and free triiodothyronine (FT3), were analyzed.A total of 1831 clinical laboratory data sets from 330 patients were analyzed. Data sets were classified into five groups (euthyroidism, hyperthyroidism, subclinical hyperthyroidism, hypothyroidism, and subclinical hypothyroidism) based on the definition of thyroid function in our hospital. Most abnormal levels of thyroid hormones were observed within the therapeutic range of serum AMD and DEA concentrations. The mean DEA/AMD ratio in the hyperthyroidism group was significantly higher than that in the euthyroidism group (0.95 +/- 0.42 vs. 0.87 +/- 0.28, p = 0.0209), and the mean DEA/AMD ratio in the hypothyroidism group was significantly lower than that in the euthyroidism group (0.77 +/- 0.26 vs. 0.87 +/- 0.28, p = 0.0038). The suppressed TSH group (0.98 +/- 0.41 vs. 0.87 +/- 0.28, p < 0.001) and the elevated FT4 level group (0.90 +/- 0.33 vs. 0.84 +/- 0.27, p = 0.0037) showed significantly higher DEA/AMD ratios compared with normal level groups. The elevated TSH group showed a significantly lower DEA/AMD ratio compared with the normal group (0.81 +/- 0.25 vs. 0.87 +/- 0.28, p < 0.0001).High and low DEA/AMD ratios were associated with AMD-induced hyperthyroidism and hypothyroidism, respectively. The DEA/AMD ratio may be a predictive marker for AMD-induced thyroid dysfunction.
  • Risk factors for amiodarone-induced thyroid dysfunction in Japan, Sayoko Kinoshita, Tomohiro Hayashi, Kyoichi Wada, Mikie Yamato, Takeshi Kuwahara, Toshihisa Anzai, Mai Fujimoto, Kouichi Hosomi, Mitsutaka Takada, JOURNAL OF ARRHYTHMIA, JOURNAL OF ARRHYTHMIA, 32(6), 474 - 480, Dec. 2016 , Refereed
    Summary:Background: Amiodarone is associated with a number of significant adverse effects, including elevated transaminase levels, pulmonary fibrosis, arrhythmia, and thyroid dysfunction. Although thyroid dysfunction is considered to be a common and potentially serious adverse effect of amiodarone therapy, the exact pathogenesis remains unknown because of its complex manifestations. Therefore, the prevalence of, and risk factors for, amiodarone-induced thyroid dysfunction in Japanese patients were investigated in the present study.Methods: A retrospective analysis of patients treated with amiodarone between January 2012 and December 2013 was performed. A total of 317 patients with euthyroidism, or subclinical hyperthyroidism or hypothyroidism, were enrolled in this study.Results: After being treated with amiodarone, 30 (9.5%) and 60 patients (18.9%) developed amiodarone-induced hyperthyroidism and amiodarone-induced hypothyroidism, respectively. Ten (33.3%) patients with amiodarone-induced hyperthyroidism and 40 (66.6%) with amiodarone-induced hypothyroidism were diagnosed within two years of the initiation of amiodarone therapy. Dilated cardiomyopathy (DCM) [Adjusted odds ratio (OR) 3.30 (95% confidence interval (CI): 1.26-8.90)1, and cardiac sarcoidosis [Adjusted OR 6.47 (95% Cl: 1.60-25.77)] were identified as predictors of amiodarone-induced hyperthyroidism. The baseline free thyroxine (T4) level [Adjusted OR 0.13 (95% Cl: 0.03-0.68)], and thyroid stimulating hormone (TSH) level [Adjusted OR1.47 (95% Cl: 1.26-1.74)] were identified as predictors of amiodarone-induced hypothyroidism.Conclusion: DCM and cardiac sarcoidosis were identified as risk factors for amiodarone-induced hyperthyroidism. Risk factors for amiodarone-induced hypothyroidism included higher baseline TSH level and lower baseline free T4 level, suggesting that subclinical hypothyroidism may be a potential risk factor for the development of amiodarone-induced hypothyroidism. (C) 2016 Japanese Heart Rhythm Society. Published by Elsevier B.V.
  • Long-term impact of therapeutic drug monitoring on the risk of hypoglycemia in HOCM patients on cibenzoline therapy, Yutaro Mukai, Kyoichi Wada, Mai Fujimoto, Kouichi Hosomi, Takeshi Kuwahara, Mitsutaka Takada, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 54(10), 795 - 803, Oct. 2016 , Refereed
    Summary:Objective: The purpose of this study was to evaluate the long-term impact of therapeutic drug monitoring (TDM) services on the risk of hypoglycemia in cibenzoline therapy. In addition, we evaluated the impact of changes in clinical setting or patient background on the risk of hypoglycemia in patients receiving cibenzoline. Methods: TDM services for cibenzoline have been performed at the Japan National Cerebral and Cardiovascular Center since March 1998. A case-control study was performed from September 2012 to February 2013, and the calculated risk of hypoglycemia associated with cibenzoline use was compared with data from our previous studies, which were performed similar to 15 years ago. Results: A significantly increased risk for hypoglycemia was observed for users of cibenzoline (adjusted OR: 2.6; 95% CI: 1.5 -4.7). In an additional analysis, the calculated risk was slightly reduced (adjusted OR; 2.1, 95% CI; 1.1 -3.8) and hypertrophic obstructive cardiomyopathy (HOCM) was identified as a possible risk factor for hypoglycemia (adjusted OR: 4.7, 95% CI: 1.8 -12.3). There was a significant difference in the mean level of cibenzoline between outpatients with and without HOCM (360.5 +/- 166.9 ng/mL vs. 276.4 +/- 136.3 ng/ mL). An inverse relationship was observed between the percentage of outpatients whose cibenzoline serum level had been measured and their risk of hypoglycemia. Conclusions: Consistent TDM services for cibenzoline have contributed to a reduced risk of hypoglycemia associated with cibenzoline therapy. Patients with HOCM have a higher risk of developing hypoglycemia. Clinicians should therefore carefully monitor serum glucose levels in patients with HOCM taking cibenzoline.
  • Association between Benzodiazepine Use and Dementia: Data Mining of Different Medical Databases, Mitsutaka Takada, Mai Fujimoto, Kouichi Hosomi, INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 13(11), 825 - 834, 2016 , Refereed
    Summary:Purpose: Some studies have suggested that the use of benzodiazepines in the elderly is associated with an increased risk of dementia. However, this association might be due to confounding by indication and reverse causation. To examine the association between benzodiazepine anxiolytic drug use and the risk of dementia, we conducted data mining of a spontaneous reporting database and a large organized database of prescriptions.Methods: Data from the US Food and Drug Administration Adverse Event Reporting System (FAERS) from the first quarter of 2004 through the end of 2013 and data from the Canada Vigilance Adverse Reaction Online Database from the first quarter of 1965 through the end of 2013 were used for the analyses. The reporting odds ratio (ROR) and information component (IC) were calculated. In addition, prescription sequence symmetry analysis (PSSA) was performed to identify the risk of dementia after using benzodiazepine anxiolytic drugs over the period of January 2006 to May 2014.Results: Benzodiazepine use was found to be associated with dementia in analyses using the FAERS database (ROR: 1.63, 95% CI: 1.61-1.64; IC: 0.66, 95% CI: 0.65-0.67) and the Canada Vigilance Adverse Reaction Online Database (ROR: 1.88, 95% CI: 1.83-1.94; IC: 0.85, 95% CI: 0.80-0.89). ROR and IC values increased with the duration of action of benzodiazepines. In the PSSA, a significant association was found, with adjusted sequence ratios of 1.24 (1.05-1.45), 1.20 (1.06-1.37), 1.23 (1.11-1.37), 1.34 (1.23-1.47), 1.41 (1.29-1.53), and 1.44 (1.33-1.56) at intervals of 3, 6, 12, 24, 36, and 48 months, respectively. Furthermore, the additional PSSA, in which patients who initiated a new treatment with benzodiazepines and anti-dementia drugs within 12- and 24-month periods were excluded from the analysis, demonstrated significant associations of benzodiazepine use with dementia risk.Conclusion: Multi-methodological approaches using different methods, algorithms, and databases suggest that long-term use of benzodiazepines and long-acting benzodiazepines are strongly associated with an increased risk of dementia.
  • Inverse Association between Sodium Channel-Blocking Antiepileptic Drug Use and Cancer: Data Mining of Spontaneous Reporting and Claims Databases, Mitsutaka Takada, Mai Fujimoto, Haruka Motomura, Kouichi Hosomi, INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 13(1), 48 - 59, 2016 , Refereed
    Summary:Purpose: Voltage-gated sodium channels (VGSCs) are drug targets for the treatment of epilepsy. Recently, a decreased risk of cancer associated with sodium channel-blocking antiepileptic drugs (AEDs) has become a research focus of interest. The purpose of this study was to test the hypothesis that the use of sodium channel-blocking AEDs are inversely associated with cancer, using different methodologies, algorithms, and databases.Methods: A total of 65,146,507 drug-reaction pairs from the first quarter of 2004 through the end of 2013 were downloaded from the US Food and Drug Administration Adverse Event Reporting System. The reporting odds ratio (ROR) and information component (IC) were used to detect an inverse association between AEDs and cancer. Upper limits of the 95% confidence interval (CI) of < 1 and < 0 for the ROR and IC, respectively, signified inverse associations. Furthermore, using a claims database, which contains 3 million insured persons, an event sequence symmetry analysis (ESSA) was performed to identify an inverse association between AEDs and cancer over the period of January 2005 to May 2014. The upper limit of the 95% CI of adjusted sequence ratio (ASR) < 1 signified an inverse association.Results: In the FAERS database analyses, significant inverse associations were found between sodium channel-blocking AEDs and individual cancers. In the claims database analyses, sodium channel-blocking AED use was inversely associated with diagnoses of colorectal cancer, lung cancer, gastric cancer, and hematological malignancies, with ASRs of 0.72 (95% CI: 0.60 - 0.86), 0.65 (0.51 - 0.81), 0.80 (0.65 - 0.98), and 0.50 (0.37 - 0.66), respectively. Positive associations between sodium channel-blocking AEDs and cancer were not found in the study.Conclusion: Multi-methodological approaches using different methodologies, algorithms, and databases suggest that sodium channel-blocking AED use is inversely associated with colorectal cancer, lung cancer, gastric cancer, and hematological malignancies.
  • Inverse Association Between Antiepileptic Drugs and Cancers; Data Mining of Large Medical Databases, Mitsutaka Takada, Mai Fujimoto, Migiwa Kanou, Kouichi Hosomi, PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 24, 451 - 452, Sep. 2015 , Refereed
  • Association between Renin-Angiotensin System Inhibitors and Cancer Risk; Data Mining of a Spontaneous Reporting Database and a Claims Database, Mai Fujimoto, Tomoya Higuchi, Kouichi Hosomi, Mitsutaka Takada, PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 24, 474 - 474, Sep. 2015 , Refereed
  • Association between Statin Use and Cancer: Data Mining of a Spontaneous Reporting Database and a Claims Database, Mai Fujimoto, Tomoya Higuchi, Kouichi Hosomi, Mitsutaka Takada, INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 12(3), 223 - 233, 2015 , Refereed
    Summary:Purpose: In recent years, the potential risk of cancer associated with statin use has been a focus of much interest. However, it remains uncertain whether statin therapy is associated with cancer risk. To examine the association between statin use and the risk of cancer, we conducted data mining using the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and a large organized database of claims constructed by a database vendor (The Japan Medical Data Center Co., Ltd, Tokyo, Japan [JMDC]).Methods: Relevant reports in the FAERS, which included data from the first quarter of 2004 through the end of 2012, were identified and analyzed. The reporting odds ratio (ROR) was used to detect spontaneous report signals and was calculated using the case/non-case method. Additionally, signals were detected via the information component (IC) using the IC025 metric. Furthermore, event sequence symmetry analysis (ESSA) was applied to identify the risk of cancer following treatment with statins over the period January 2005 to July 2013.Results: In the FAERS database analyses, significant signals for colorectal cancer and pancreatic cancer were found for statins as a class. In the ESSA, significant associations between statin use and colorectal cancer and pancreatic cancer were found, with adjusted sequence ratios (95% confidence intervals) of 1.20 (1.08-1.34) and 1.31 (1.13-1.53), respectively, at an interval of 48 months.Conclusions: Multi-methodological approaches using different algorithms and databases suggest that statin use is associated with an increased risk for colorectal cancer and pancreatic cancer.
  • Association of statin use with storage lower urinary tract symptoms (LUTS): data mining of prescription database, Mai Fujimoto, Tomoya Higuchi, Kouichi Hosomi, Mitsutaka Takada, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 52(9), 762 - 769, Sep. 2014 , Refereed
    Summary:Objective: The efficacy and safety of statins have been studied in a number of clinical trials and epidemiological studies. In recent years, the Medicine and Healthcare Products Regulatory Agency (MHRA) has assessed the evidence available on the following adverse reactions associated with the use of statins: sleep disturbances, memory loss, micturition disorders (problems with urination), sexual disturbances, depression, and interstitial pneumopathy. However, the association between statin use and the risk of these adverse reactions remains unclear. To examine the association between statin use and the risk of lower urinary tract symptoms (LUTS) or the disorder causing LUTS, we carried out data mining using a prescription database. Methods: A large organized database of prescriptions constructed by a database vendor was used in the study. Symmetry analysis was used to identify the risk of LUTS after using statins over the period January 2006 to August 2013. Statin use in combination with drugs administered for storage LUTS was examined by prescription sequence symmetry analysis (PSSA). Results: A significant association between statins and drugs for storage LUTS was found, with adjusted sequence ratios (ASRs) of 1.21 (95% CI, 1.00-1.46), 1.19(95% CI, 1.04-1.38), and 1.17 (95% CI, 1.05-1.30) for intervals of 91, 182, and 365 days, respectively. In the analyses of individual statins, significant associations were found only for pravastatin. Significant associations with individual drugs for storage LUTS were found for solifenacin succinate with ASRs of 1.36 (95% CI, 1.02-1.81), 1.48 (95% CI, 1.19-1.84), and 1.47 (95% CI, 1.25-1.73) for intervals of 91, 182, and 365 days, for fiavoxate hydrochloride with an ASR of 1.56 (95% CI, 1.13-2.17) at an interval of 182 days, and for oxybutynin hydrochloride with ASRs of 2.06(95% CI, 1.11-3.94) and 1.71 (95% CI, 1.09-2.72) at intervals of 182 and 365 days. Significant associations with gender were found only in females with ASRs of 1.25(95% CI, 1.04-1.51) and 1.23(95% CI, 1.07-1.41) at intervals of 182 and 365days, respectively. Conclusions: Analysis of the prescription database showed significant association for storage LUTS in statin users.
  • Association of Statin Use with Sleep Disturbances: Data Mining of a Spontaneous Reporting Database and a Prescription Database (vol 37, pg 421, 2014), Mitsutaka Takada, Mai Fujimoto, Kohei Yamazaki, Masashi Takamoto, Kouichi Hosomi, DRUG SAFETY, DRUG SAFETY, 37(8), 653 - 653, Aug. 2014 , Refereed
  • Association of Statin Use with Sleep Disturbances: Data Mining of a Spontaneous Reporting Database and a Prescription Database, Mitsutaka Takada, Mai Fujimoto, Kohei Yamazaki, Masashi Takamoto, Kouichi Hosomi, DRUG SAFETY, DRUG SAFETY, 37(6), 421 - 431, Jun. 2014 , Refereed
    Summary:Particular interest has been generated regarding the possible influence of statin use on sleep quality. However, no conclusive evidence exists that a particular statin is more likely to be associated with sleep disturbances versus others. It remains uncertain whether different statins produce different risks for sleep disturbance.To examine the association between statin use and the risk of sleep disturbances, we conducted data mining using the US Food and Drug Administration Adverse Event Reporting System (FAERS) and a large organized database of prescriptions constructed by a database vendor (Japan Medical Information Research Institute, Inc. Japan).Relevant reports in the FAERS were identified and analyzed. Data from the first quarter of 2004 through the end of 2013 were included in this study. The reporting odds ratio (ROR) was used to detect spontaneous report signals, calculated using the case/non-case method. For the ROR, a signal was detected if the lower limit of 95 % two-sided confidence interval (95 % CI) was > 1. Additionally, signal detection using the IC was conducted using the IC025 metric, a lower limit of the 95 % CI of the IC, where a signal is detected if the IC025 value exceeds 0. In addition, symmetry analysis was used to identify the risk of insomnia after using statins over the period of January 2006 to August 2013.In the analyses of the FAERS database, significant signals for sleep disturbances including disturbances in initiating and maintaining sleep, sleep disorders NEC, sleeping disorders due to a general medical condition, and parasomnias were found. In the prescription sequence symmetry analysis, a significant association between statin use and hypnotic drug use was found, with adjusted sequence ratios of 1.14 (1.03-1.26), 1.20 (1.11-1.29), and 1.18 (1.11-1.25) at intervals of 91, 182, and 365 days, respectively.Multi-methodological approaches using different algorithms and databases strongly suggest that statin use is associated with an increased risk for sleep disturbances including insomnia.
  • Statin-associated lower urinary tract symptoms: data mining of the public version of the FDA adverse event reporting system, FAERS, Mai Fujimoto, Kouichi Hosomi, Mitsutaka Takada, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 52(4), 259 - 266, Apr. 2014 , Refereed
    Summary:Objective: To examine the association between statin use and the risk of lower urinary tract symptoms (LUTS) in reports submitted to the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) between 2004 and 2011.Methods: Relevant reports in the FAERS were identified and analyzed. The reporting odds ratio (ROR) was used to detect spontaneous report signals, calculated using the case/non-case method. Cases were identified by the presence of reports of an adverse drug reaction (ADR) in which statins were the suspected drug. Non-cases were all the reports of the same reactions induced by drugs other than statins. The reporting odds ratio (ROR) and 95% confidential interval (CI) was calculated as a measure of disproportionality.Results: A total of 44,959,104 drug-reaction pairs was found in 2,681,739 reports. Significant RORs were found for both voiding (ROR; 1.16,95% CI; 1.10 - 1.23) and storage symptoms (ROR; 1.25, 95% CI; 1.20 - 1.30). Analysis of individual statins showed that rosuvastatin, atorvastatin, and lovastatin had significant disproportionality for voiding symptoms, while simvastatin, rosuvastatin, pravastatin, atorvastatin, pitavastatin, and lovastatin had significant disproportionality for storage symptoms. Of the four voiding symptoms, significant RORs were found for urine flow decrease and dysuria. Of the four storage symptoms, significant RORs were found for pollakiuria and nocturia. No fundamental differences in disproportionality were observed between genders.Conclusions: Analysis of the FAERS database showed small but reliable signals for LUTS in statin users. The mechanism responsible for these reactions is unknown. However, these adverse events should be monitored closely.
  • Difference in risk of gastrointestinal complications between users of enteric-coated and buffered low-dose aspirin, Mitsutaka Takada, Mai Fujimoto, Kouichi Hosomi, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 52(3), 181 - 191, Mar. 2014 , Refereed
    Summary:Objective: Difference in the risk of gastrointestinal (GI) complications between users of enteric-coated and buffered low-dose aspirin (LDA) is unclear. The purpose of the study is to examine the difference in risk of GI damage between enteric-coated and buffered LDA products. Methods: A large and chronologically organized receipt database constructed by a database vendor was utilized. Prescription and event sequence symmetry analysis was used to identify the risk of LDA-induced GI complications over the period from January 2005 to July 2011. LDA use in combination with H2-receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) was examined by prescription sequence symmetry analysis. Likewise, symmetry analysis was undertaken to evaluate the association between the diagnosis of GI disease and the prescription of LDA products. Results: In July 2011, enteric-coated LDA users were more frequently co-administered PPIs than buffered LDA users (25.4% vs. 14.4%). Prescription sequence symmetry analysis of acid inhibitor use found no significant associations with enteric-coated LDA use and buffered LDA use. The event sequence symmetry analysis of ulcer, gastritis and duodenitis, and melena found significant associations with enteric-coated LDA use, with adjusted sequence ratios (ASRs) of 1.58 (1.23 - 2.06), 1.30 (1.03 - 1.65), and 14.38 (2.19 - 607.95), respectively, at the 6-month interval. At the 12-month interval, analysis of ulcers and melena found significant associations for enteric-coated LDA users, with ASRs of 1.39 (1.13 - 1.73) and 20.83 (3.33 - 863.25), respectively. Conclusions: Our findings do not support that there is no difference in the risk of GI complications between enteric-coated LDA and buffered LDA, but rather may imply that the risk of GI complications associated with enteric-coated LDA is higher than that with buffered LDA.
  • Difference between the frequencies of antisecretory drug prescriptions in users of buffered vs. enteric-coated low-dose aspirin therapies, Hiroko Hachiken, Ai Murai, Kyoichi Wada, Takeshi Kuwahara, Kouichi Hosomi, Mitsutaka Takada, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 51(10), 807 - 815, Oct. 2013 , Refereed
    Summary:Objective: To provide further insights on the risks of gastrointestinal (GI) complications in individuals using low-dose aspirin (LDA), we investigated the concomitant use of LDA and antisecretory drugs. Additionally, we examined the frequency distributions of prescribing sequences for LDA and antisecretory drugs. Methods: Data from a computerized prescription order entry system was analyzed at the National Cerebral and Cardiovascular Center of Japan. LDA use in combination with H2-receptor antagonists (H2RAs) and proton pomp inhibitors (PPIs) was examined over the period from January 2001 to December 2010. Prescription sequence symmetry analyses were used to identify LDA-induced H2RAs or PPIs users. Results: In December 2010, PPIs accounted for 9.9% of the prescriptions for buffered LDA users and 16.1% of those for enteric-coated LDA users. Incident use of PPIs occurred more frequently among enteric-coated LDA users than buffered LDA users (17.6% vs. 11.0%, respectively). Prescription sequence symmetry analyses of PPI use revealed significant associations with enteric-coated LDA use, resulting in adjusted sequence ratios of 1.82 (95%CI, 1.11 - 3.03) and 1.87 (95% CI, 1.26 - 2.83) at intervals of 182 and 365 days, respectively. Enteric-coated LDA users tended to initiate PPI therapy on the same date more frequently than buffered LDA users (35.1% vs. 10.8%, respectively). Conclusions: Our findings do not support the notion that enteric-coated LDA products confer a lower risk for GI complications than buffered formulations, but may conversely imply that the risk of GI complications associated with buffered LDA is lower than that of enteric-coated LDA.
  • Coloration of phenothiazines with metal-containing drugs, Kouichi Hosomi, Akihiro Okuno, Yoshiharu Umetani, Teruhisa Araya, Kenji Matsuyama, Jun Haginaka, Masaki Mifune, Yutaka Saito, Yakugaku Zasshi, Yakugaku Zasshi, 124(9), 587 - 598, Sep. 2004 , Refereed
    Summary:We studied the color change of phenothiazines and metal-containing drugs after compound formation, followed by use of FT-Raman spectrocopy to observe any structural changes in them. When 6 phenothiazines (thioridazine hydrochloride, prochlorperazine maleate, levomepromazine maleate, chlorpromazine phenolphthalinate, fluphenazine maleate and perphenazine fendiate) formed compounds with natural aluminum silicate, the color change was accompanied by a shift of FT-Raman signals. These changes could be attributed to the structural changes of phenothiazines. This present observation can be then used in advance to avoid coloration of phenothiazines during preparative procedures with metal-containing drugs such as antacids. © 2004 The Pharmaceutical Society of Japan.
  • An Asymmetric Nitroolefination of α-Alkyl-γ-and δ-Lactones with Modified Nitroenamines, Kiyoharu Nishide, Ryuichi Kurosaki, Kouichi Hosomi, Hitoshi Imazato, Takehisa Inoue, Manabu Node, Toshiumi Ohmori, Kaoru Fuji, Tetrahedron, Tetrahedron, 51(40), 10857 - 10866, Oct. 02 1995 , Refereed
    Summary:New chiral nitroenamines 4a,b having (S)-2-t-butyldimethylsiloxymethylpyrrolidine as an auxiliary were found to be very effective for asymmetric nitroolefination of α-alkyl-γ- and δ-lactones. The enantiomeric excess of the product increased remarkably in the reaction with γ-lactones compared with previous nitroenamines 1a,b. A possible chelation model for the transition state of the asymmetric nitroolefination is discussed. © 1995 Elsevier Science Ltd.
  • An improved asymmetric nitroolefination of α-alkyl-γ- and δ-lactones with modified nitroenamines, Manabu Node, Ryuichi Kurosaki, Kouichi Hosomi, Takehisa Inoue, Kiyoharu Nishide, Toshiumi Ohmori, Kaoru Fuji, Tetrahedron Letters, Tetrahedron Letters, 36(1), 99 - 102, Jan. 02 1995 , Refereed
    Summary:New chiral nitroenamines 4a,b were found to be very effective for asymmetric nitroolefination of α-alkyl-γ- and δ-lactones. The enantiomeric excess of the product ran up to 99 %. A possible chelation model for the transition state of the asymmetric nitroolefination was discussed. © 1994.
  • Enantioselective reduction of σ-Symmetric bicyclo[3.3.0]octane-2,8-diones with baker's yeast, Takehisa Inoue, Kouichi Hosomi, Mamoru Araki, Kiyoharu Nishide, Manabu Node, Tetrahedron: Asymmetry, Tetrahedron: Asymmetry, 6(1), 31 - 34, Jan. 1995 , Refereed
    Summary:σ-Symmetric bicyclic diketones 8a-c were enantioselectively reduced with baker's yeast to give the chiral hydroxy ketones 7a-c in 74-;100% ee. The reduction product (+)-7a and (-)-7′c were shown to be the chiral intermediates for the total synthesis of cantabrenonic acids derivatives 3 and hirsutene (4), respectively. The subsequent transformation of (+)-7a gave the intermediate (+)-5 for the total synthesis of capnellenols (1, 2). © 1994.

Conference Activities & Talks

  • 抗不整脈薬による癌罹患リスクの関連性の解析 有害事象自発報告データベースを用いて, 細見 光一, 保田 彩夏, 藤本 麻依, 高田 充隆, 日本医薬品情報学会総会・学術大会講演要旨集,   2016 05
  • 糖尿病治療薬使用と癌罹患リスクの関連性の解析―有害事象自発報告データベースを用いて―, 細見光一, 浦田佳奈子, 藤本麻依, 高田充隆, 日本薬学会年会要旨集(CD-ROM),   2016 03
  • 有害事象自発報告データベースを用いた抗不整脈薬による有害事象の網羅的解析, 保田 彩夏, 細見 光一, 藤本 麻依, 高田 充隆, 日本医薬品情報学会総会・学術大会講演要旨集,   2015 06
  • 有害事象自発報告データベースを用いた抗うつ薬・抗パーキンソン病薬と認知障害の解析, 小西 啓介, 細見 光一, 藤本 麻依, 高田 充隆, 日本医薬品情報学会総会・学術大会講演要旨集,   2015 06
  • 大規模医療データベースを用いた抗てんかん薬とがんリスクの関連性に関する研究, 本村 春香, 藤本 麻依, 細見 光一, 高田 充隆, 日本医薬品情報学会総会・学術大会講演要旨集,   2015 06
  • 大規模医療データベースを用いた各種医薬品と認知症との関連性に関する研究, 森本早矢香, 藤本麻衣, 細見光一, 高田充隆, 医療薬学フォーラム講演要旨集,   2015 06
  • 有害事象自発報告データベースを用いたリスクシグナルライブラリーの構築―糖尿病治療薬による有害事象のスクリーニング―, 浦田佳奈子, 細見光一, 藤本麻依, 高田充隆, 医療薬学フォーラム講演要旨集,   2015 06
  • 有害事象自発報告データベース解析のドラッグ・リポジショニングへの応用に関する研究―ACE阻害薬およびアンジオテンシン受容体遮断薬と消化管出血との関係―, 赤坂英里加, 藤本麻衣, 細見光一, 高田充隆, 医療薬学フォーラム講演要旨集,   2015 06
  • 日米の有害事象自発報告データベースを用いた心不全及び浮腫の解析, JOMOTO KAYO, HOSOMI KOICHI, FUJIMOTO MAI, TAKATA MICHITAKA, 日本薬学会年会要旨集(CD-ROM),   2015 03
  • 抗精神病薬使用と錐体外路症状の関連性の解析―ナショナルデータベースを用いて―, HOSOMI KOICHI, 日本薬学会年会要旨集(CD-ROM),   2015 03
  • 高血圧治療薬によるGERDおよび誤嚥性肺炎の解析―日米の有害事象自発報告データベースを用いて―, HASHIMOTO MASAYUKI, HOSOMI KOICHI, FUJIMOTO MAI, TAKATA MICHITAKA, 日本薬学会年会要旨集(CD-ROM),   2015 03
  • 有害事象自発報告データベースを用いたβ受容体関連薬剤による血中カリウム値への影響の解析, UMEMOTO AKIRA, HOSOMI KOICHI, FUJIMOTO MAI, TAKATA MICHITAKA, 日本薬学会年会要旨集(CD-ROM),   2015 03
  • 有害事象自発報告データベースを用いた糖尿病薬の有害事象の解析, URATA KANAKO, HOSOMI KOICHI, FUJIMOTO MAI, TAKADA MITSUTAKA, 日本薬学会年会要旨集(CD-ROM),   2015 03
  • PMDA医薬品副作用データベースを用いた漢方製剤の安全性シグナルの解析, MASUI REIKA, HOSOMI KOICHI, FUJIMOTO MAI, TAKATA MICHITAKA, 日本薬学会年会要旨集(CD-ROM),   2015 03
  • PMDA医薬品副作用データベースを用いた漢方製剤の安全性シグナルの解析, HOSOMI KOICHI, MASUI REIKA, FUJIMOTO MAI, TAKADA MITSUTAKA, 日本医薬品情報学会総会・学術大会講演要旨集,   2014 07
  • スタチン系薬剤による糖尿病発症のリスク―処方せんデータによる解析―, KARINO MIGIWA, FUJIMOTO MAI, HOSOMI KOICHI, TAKADA MITSUTAKA, 医療薬学フォーラム講演要旨集,   2014 06
  • PMDA医薬品副作用データベースを用いた安全性シグナルの解析―横紋融解症,悪性症候群,アナフィラキシー反応,スティーブンス・ジョンソン症候群,中毒性表皮壊死症―, MASUI REIKA, HOSOMI KOICHI, FUJIMOTO MAI, TAKADA MITSUTAKA, 医療薬学フォーラム講演要旨集,   2014 06
  • 処方箋データベースを用いたHMG‐CoA還元酵素阻害薬であるスタチン系薬剤による睡眠障害の解析, TAKAMOTO SHINJI, FUJIMOTO MAI, HOSOMI KOICHI, TAKADA MITSUTAKA, 医療薬学フォーラム講演要旨集,   2014 06
  • データマイニング手法によるオピオイド受容体鎮痛薬の安全性シグナルの解析―ペンタゾシンと急性膵炎の関連性―, NITTA MASAYUKI, HOSOMI KOICHI, FUJIMOTO MAI, TAKADA MITSUTAKA, 医療薬学フォーラム講演要旨集,   2014 06
  • 日米の有害事象自発報告データベースを用いたSMQ分類による有害事象別性差の解析, NORIMOTO KAYO, HOSOMI KOICHI, FUJIMOTO MAI, TAKADA MITSUTAKA, 医療薬学フォーラム講演要旨集,   2014 06
  • 処方せんデータを用いたスタチン系薬剤と蓄尿症状の関連性についての研究, HIGUCHI TOMOYA, FUJIMOTO MAI, HOSOMI KOICHI, TAKADA MITSUTAKA, 医療薬学フォーラム講演要旨集,   2014 06
  • スタチン系薬剤使用と下部尿路機能障害・睡眠障害の関連性―処方せんデータを用いた解析―, 藤本麻依, 樋口智也, 高本真志, 狩野汀, 細見光一, 高田充隆, 日本薬学会年会要旨集(CD-ROM),   2014 03
  • PMDA医薬品副作用データベース(JADER)を用いた各種安全性シグナルの解析, 細見光一, 朴ピナウル, 増井怜香, 藤本麻依, 高田充隆, 日本薬学会年会要旨集(CD-ROM),   2014 03
  • アンジオテンシンII受容体拮抗薬及びACE阻害薬によるがん発症リスクの検討―データベースを用いた解析―, KARINO MIGIWA, FUJIMOTO MAI, HOSOMI KOICHI, TAKADA MITSUTAKA, 生体機能と創薬シンポジウム要旨集,   2014
  • 各種データベースを用いたスタチン系薬剤と膀胱がんとの関連性についての研究, HIGUCHI TOMOYA, FUJIMOTO MAI, HOSOMI KOICHI, TAKADA MITSUTAKA, 生体機能と創薬シンポジウム要旨集,   2014
  • 処方せんデータベースを用いたスタチン系薬剤使用と睡眠障害・うつ症状の関連性について, 高本真志, 藤本麻依, 細見光一, 高田充隆, 生体機能と創薬シンポジウム要旨集,   2014
  • スタチン系薬剤による蓄尿機能障害の副作用リスクに関する研究, 田村美加子, 藤本麻依, 細見光一, 高田充隆, 生体機能と創薬シンポジウム要旨集,   2014
  • 日米の有害事象自発報告データベースを用いたニューキノロン系抗菌薬による有害事象の解析, 新居万莉, 細見光一, 藤本麻依, 高田充隆, 日本薬剤師会学術大会講演要旨集,   2013 09
  • 兵庫県ママサポート薬剤師による地域の子育て支援の実践と課題, 細見尚子, 下田幸枝, 細見光一, 高田充隆, 日本薬剤師会学術大会講演要旨集,   2013 09
  • 日米の有害事象自発報告データベースを用いた厚生労働省の重篤副作用疾患別対応マニュアルの解析, 福田亜矢, 細見光一, 藤本麻依, 高田充隆, 日本薬剤師会学術大会講演要旨集,   2013 09
  • 日米の有害事象自発報告データベースを用いた定型及び非定型抗精神病薬による有害事象の解析, 朴ピナウル, 細見光一, 豕瀬諒, 藤本麻依, 高田充隆, 日本薬剤師会学術大会講演要旨集,   2013 09
  • 日米の有害事象自発報告データを用いたβ遮断薬の薬剤選択の指針に対する安全性の検討, 梅本晃良, 細見光一, 藤本麻依, 高田充隆, 日本医薬品情報学会総会・学術大会講演要旨集,   2013 08 01
  • 医薬品副作用被害救済制度の実態把握, 青山友紀, 細見光一, 藤本麻依, 高田充隆, 日本医薬品情報学会総会・学術大会講演要旨集,   2013 08 01
  • 日米の有害事象自発報告データを用いたHMG‐CoA還元酵素阻害薬の有害事象の解析, 村上兆司, 細見光一, 藤本麻依, 高田充隆, 日本医薬品情報学会総会・学術大会講演要旨集,   2013 08 01
  • 加速度センサを用いた調剤技能の動作解析, 松野純男, 朝倉南美, 齊藤美穂, 波部斉, 細見光一, 大星直樹, 高田充隆, 日本薬学会年会要旨集(CD-ROM),   2013 03
  • 重篤副作用疾患別対応マニュアルを補完する有害事象自発報告データベースの解析, 細見光一, 福田亜矢, 高田充隆, 日本薬学会年会要旨集(CD-ROM),   2013 03
  • FDA有害事象自発報告データベースを用いた抗凝固薬による消化器関連事象の比較, 真鍋彩香, 河内正二, 井上和香, 細見光一, 高田充隆, 濱口常男, 日本薬学会年会要旨集(CD-ROM),   2013 03
  • 有害事象自発報告データベースを用いたニューキノロン系抗菌薬とNSAIDsの併用による痙攣事象の解析, 細見光一, 新居万莉, 高田充隆, 日本薬剤師会学術大会講演要旨集,   2012 10
  • 有害事象自発報告データベースを用いた甲状腺機能異常事象の解析, 福田亜矢, 細見光一, 高田充隆, 日本医薬品情報学会総会・学術大会講演要旨集,   2012 06 10
  • 臨床に活用される医薬品情報を指向した有害事象自発報告データの解析, 細見光一, 日本医薬品情報学会総会・学術大会講演要旨集,   2012 06 10
  • 有害事象自発報告データベースを用いたニューキノロン系抗菌薬とNSAIDsの併用による痙攣事象の解析, 新居万莉, 細見光一, 高田充隆, 日本医薬品情報学会総会・学術大会講演要旨集,   2012 06 10
  • 関節リウマチ治療における生物学的製剤による安全性シグナル指標RORの解析, 細見光一, 豕瀬諒, 朴ピナウル, 高田充隆, 日本薬学会年会要旨集,   2012 03 05
  • 在宅医療実施による薬剤師の意識変化~テキストマイニングによるあぶり出し~, 李繭香, 堀野智美, 大和幹枝, 高橋直子, 岸田充生, 細見光一, 藤垣哲彦, 松野純男, 北小路学, 高田充隆, 日本薬学会年会要旨集,   2012 03 05
  • アスピリン使用時における医薬品併用による安全性シグナル指標RORの解析, 細見光一, 炭床啓太, 宮本秀彰, 高田充隆, 日本薬剤疫学会学術総会抄録集,   2011 11
  • 患者から訴えが出やすい有害事象と起因薬剤は何か?―FDA大規模有害事象自発報告(AERS)の解析から―, 細見光一, 炭床啓太, 宮本秀彰, 高田充隆, 日本薬学会年会要旨集,   2011 03 05
  • アスピリンによる消化管障害はレニン・アンジオテンシン系阻害薬によって抑制されるのか―FDA大規模有害事象自発報告(AERS)の解析から―, 炭床啓太, 細見光一, 宮本秀彰, 高田充隆, 日本薬学会年会要旨集,   2011 03 05
  • 薬局薬剤師の在宅医療への参画の現状~主要な問題点の抽出とその原因の解析~, 李繭香, 北小路学, 岸田充生, 高橋直子, 細見光一, 松野純男, 高田充隆, 日本薬学会年会要旨集,   2011 03 05
  • 6年制長期実務実習第1期に関する学生アンケート調査:Customer Satisfaction(CS)分析により抽出された改善項目, 村上悦子, 大鳥徹, 高田充隆, 小竹武, 細見光一, 北小路学, 井上知美, 八軒浩子, 松山賢治, 日本薬学会年会要旨集,   2011 03 05
  • Trend Analysis of Japanese Journal Articles on Medical Pharmacy Using Text Mining, 後藤佐昌子, 八軒浩子, 細見光一, 北小路学, 高田充隆, 医療薬学フォーラム講演要旨集,   2010 07
  • 抗癌剤に対して不安が強い患者への薬剤指導骨髄移植予定の2症例を通して, 高柳信子, 奥野昌宏, 細見光一, 中田学, 梅谷義晴, 高宮静男, 高蓋寿郎, 日本医療薬学会年会講演要旨集,   2009 09 15
  • 抗がん剤無菌調製時における感染対策の現状についての報告, 大東芳子, 権藤直人, 橋田亨, 中浴伸二, 林三千雄, 坂本悦子, 岡田裕, 藤井宏, 俣木陽子, 小林佑子, 山本剛, 熊木まゆ子, 細見光一, 庄司知世, 日本環境感染学会誌,   2009 01 13
  • NST新聞の発刊の意義~NST広報の役割を通して~, 奥野昌宏, 宮崎純子, 藤本麻依, 高柳信子, 佐藤智子, 中田学, 細見光一, 静脈経腸栄養,   2009 01 01
  • がん化学療法への薬剤師の関わり―がん化学療法の投与中止理由の解析―, 細見光一, 妹川信一, 山崎貴之, 鈴岡広恵, 橋本勝, 日本薬学会年会要旨集,   2008 03 05
  • NST薬剤師の役割~回診時の情報提供を通して~, 佐藤智子, 奥野昌宏, 宮崎純子, 藤本麻依, 高柳信子, 細見光一, 橋本勝, 大西伸策, 静脈経腸栄養,   2008 01 15
  • 効率的な調剤業務をめざして‐全自動散薬分包機135包型の有用性の検討‐, 細見光一, 亀本みの子, 久保知子, 藤井延子, 橋本勝, 大西伸策, 日本薬剤師会学術大会講演要旨集,   2007 10
  • 病院実務研修(大学院医療薬学コース)で得た医療を考える力一妊婦・授乳婦の薬のサポートをめざして―, 田村理絵, 細見光一, 上田浩貴, 佐藤智子, 久保嘉靖, 藤本麻依, 中田学, 橋本勝, 岩川精吾, 大西伸策, 日本薬学会年会要旨集,   2007 03 05
  • 病院実務研修で得た医療を考える力―調剤支援システムを活用した注射薬調製業務の効率化―, 上田浩貴, 細見光一, 田村理絵, 妹川信一, 山崎貴之, 家村恵, 宮崎純子, 佐藤智子, 久保知子, 藤本麻依, 鈴岡広恵, 村山慶, 向井孝介, 岩川精吾, 橋本勝, 大西伸策, 日本薬学会年会要旨集,   2007 03 05
  • NST回診時における薬剤師の役割―当院作成「NST薬剤師回診マニュアル」を通して―, 奥野昌宏, 高柳信子, 橋本勝, 細見光一, 大西伸策, 松本美穂, 高宮静男, 井谷智尚, 京極高久, 草野仁, 静脈経腸栄養,   2007 01 15
  • 当院の外来がん化学療法におけるFOLFOX療法の現状調査~薬剤師のがん化学療法への積極的な参加に向けて~, 久保嘉靖, 細見光一, 妹川信一, 家村恵, 佐藤智子, 久保知子, 宮崎純子, 藤本麻依, 橋本勝, 長谷川寛, 奥野敏隆, 京極高久, 林雅造, 井谷智尚, 三村純, 猪熊哲朗, 福田真由美, 大西伸策, 日本癌治療学会誌,   2006 09 04
  • 薬剤師による注射薬調製業務の経済性を考える―外来がん化学療法への薬剤師の関わりから―, 細見光一, 藤本麻依, 妹川信一, 家村恵, 久保嘉靖, 宮崎純子, 佐藤智子, 久保知子, 橋本勝, 大西伸策, 日本医療薬学会年会講演要旨集,   2006 09 01
  • 薬剤師による注射薬調製業務の経済性を考える―外来がん化学療法における薬剤師業務の展開から―, 藤本麻依, 細見光一, 妹川信一, 家村恵, 久保嘉靖, 宮崎純子, 佐藤智子, 久保知子, 橋本勝, 大西伸策, 医療薬学フォーラム講演要旨集,   2006 07
  • 病院実務実習(大学院医療薬学コース)で得た医療を考える力‐注射薬調剤業務におけるリスクマネジメントへの取り組み‐, 塩野州平, 細見光一, 家村恵, 久保嘉靖, 妹川信一, 宮崎純子, 佐藤智子, 久保知子, 藤本麻依, 橋本勝, 津田泰男, 太田光よし, 大西伸策, 日本薬学会年会要旨集,   2006 03 06
  • 注射薬調剤支援システムはどこまで有効活用できるのか, 宮崎純子, 細見光一, 妹川信一, 久保嘉靖, 津田泰男, 大西伸策, 日本医療薬学会年会講演要旨集,   2005 09 01
  • Contribution of medication guidance to psychosomatic medicine-The role of the pharmacist in integrated treatment for blood cancer chemotherapy-,   2005 08
  • 薬・薬・学連携をめざした勉強会(神戸薬学ネットワーク)の取り組み, 金啓二, 西田英之, 東和夫, 池田りき子, 大川恭子, 魚本智子, 小野達也, 河本由紀子, 清原義史, 沢崎高志, 細見光一, 室井延之, 大野真理子, 緒方園子, 大西憲明, 福島昭二, 徳山尚吾, 平井みどり, 松山賢治, 日本医療薬学会年会講演要旨集,   2004 09 01
  • 注射薬自動払出し装置導入による評価と課題, 宮崎純子, 細見光一, 妹川信一, 久保嘉靖, 津田泰男, 大西伸策, 日本医療薬学会年会講演要旨集,   2004 09 01
  • 新薬情報入手に関するアンケート調査, 清原義史, 前田温, 大川恭子, 細見光一, 平野泰健, 河本由紀子, 大西憲明, 平井みどり, 松山賢治, 日本医療薬学会年会講演要旨集,   2004 09 01
  • 学生実習の受け入れをどう考えていくべきか, 細見光一, 室井延之, 東和夫, 池田りき子, 魚本智子, 大川恭子, 笠井真二, 河本由紀子, 清原義史, 日本薬剤師会学術大会講演要旨集,   2003 10 12
  • 点眼剤における保存剤の検討~先発医薬品と後発医薬品の比較~, 久保嘉靖, 細見光一, 奥野昌宏, 神代知子, 橋本勝, 顕谷昭久, 平井みどり, 日本医療薬学会年会講演要旨集,   2003 09 01
  • The Role of Pharmaceutical Care for the Parents with Children Receiving Chemotherapy for Leukemia : Through Pharmaceutical Care for Two Cases of Acute Lymphocytic Leukemia, OKUNO Akihiro, HOSOMI Kouichi, MAEKAWA Megumi, UMETANI Yoshiharu, ARAYA Teruhisa, YAMAMOTO Kinya, TAKAMIYA Shizuo, SATO Tomoaki, MATSUBARA Kousaku, BABA Kunizo, 子どもの心とからだ : 日本小児心身医学会雑誌 : journal of Japanese Society of Psychosomatic Pediatrics,   2002 06 15
  • フェノチアジン系薬剤と金属含有薬剤の配合変化, 細見光一, 奥野昌宏, 梅谷義晴, 顕谷昭久, 松山賢治, 萩中淳, 御船正樹, 斎藤寛, 日本薬学会年会要旨集,   2002 03 05
  • 小児がん化学療法に対する親への薬剤指導 急性リンパ性白血病の2症例を通して, 奥野 昌宏, 細見 光一, 前川 恵, 佐藤 智子, 梅谷 義晴, 顕谷 昭久, 山本 欣哉, 高宮 静男, 佐藤 倫明, 針谷 秀和, 日本児童青年精神医学会総会抄録集,   2000 10
  • An Improved Asymmetric Nitroolefination of .ALPHA.-Alkyl-.GAMMA.-and .DELTA.-lactones with Modified Nitroenamines and Its Application to the Synthesis of (-)-Aphanorphine., 野出学, 黒崎竜一, 細見光一, 今里均, 井上武久, 西出喜代治, 反応と合成の進歩シンポジウム講演要旨集,   1994 10
  • 33 Preparation of Chiral Bicyclo[3.3.0]octanes by Enzymatic Methods and Their Application to the Natural Products Syntheses, Inoue T, Araki M, Hosomi K, Okamoto K, Node M, 天然有機化合物討論会講演要旨集,   1994 09 20
    Summary:Chiral bicyclo[3.3.0]octane derivatives 1 are useful as chiral synthons for efficient synthesis of cyclic natural products. Here we describe the asymmetric transformation using enzymatic method of δ-symmetric bicyclic diketones 2a-c and tetraester 9, and the application of chiral bicyclo[3.3.0]octane derivatives [(+)-3b, (+)- and (-)-11] to natural products syntheses. 1. Baker's yeast-mediated asymmetric reduction of δ-symmetric bicyclic diketones 2a-c afforded the optical active ketols 3a-d in excellent enantioselectivity. Especially, ketol (+)-3b was the chiral intermediate for the total syntheses of (-)-cantabrenonic acids. Furthermore, usefulness of (+)-3b as a chiral bicyclic synthon was revealed by the short transformation of the ketol to the chiral intermediate (+)-4 in (+)-capnellenols syntheses (Scheme 5). 2. PPL-mediated asymmetric demethoxycarbonylation of achiral tetraester 9 obtained by Weiss reaction afforded the chiral triester (+)-10 in 98.3 %ee. The chiral triester was selectively demethoxycarbonylated to prepare chiral C_2-symmetry diester (+)-11. On the other hand, lipase AY-mediated asymmetric demethoxycarbonylation of achiral tetraester 9 directly afforded the chiral C_2-symmetry diester (-)-11 (100 %ee), having opposite chirality compared to the reaction with PPL. The results of lipase-mediated asymmetric transformation of achiral tetraester 9 are shown in Table 1. The chiral diesters (+)- and (-)-11 were very useful as chiral C_2-symmetry synthons for the total syntheses of (+)-carbacyclin, (-)-isoiridomyrmecin, (-)-ajmalicine (Scheme 7, 8, and 9).
  • Preparation of Chiral Bicyclo 3.3.0 octanes by Enzymatic Methods and Their Application to the Natural Products Syntheses., INOUE TAKEHISA, ARAKI MAMORU, HOSOMI KOICHI, OKAMOTO KEN, NODE MANABU, 天然有機化合物討論会講演要旨集,   1994 09
  • パン酵母を用いるσ‐対称[3.3.0]Octane類の不斉変換反応, 井上武久, 細見光一, 北川豊, 野出学, 日本薬学会年会要旨集,   1993 03
  • 不斉ニトロオレフィン化反応の改良, 井上武久, 細見光一, 黒崎竜一, 野出学, 冨士薫, 日本薬学会年会要旨集,   1993 03
  • 光学活性三環性セキステルペン類全合成のための重要中間体の不斉合成研究, 井上武久, 細見光一, 野出学, 香料・テルペンおよび精油化学に関する討論会講演要旨集,   1992 10

Misc

  • 医療データベースと遺伝子発現データベースの統合解析によるジゴキシンの新規薬効探索, 横山聡, 杉本泰浩, 中川千拓, 細見光一, 高田充隆, 日本薬学会年会要旨集(CD-ROM), 139年会, 4, 97, 97,   2019 03 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201902224901705996
  • モルヒネとベンゾジアゼピン併用による呼吸抑制増強の検討, 玉田実花, 浦田航希, 橋本昌子, 細見光一, 高田充隆, 荒井國三, 日本薬学会年会要旨集(CD-ROM), 139年会, 4, 184, 184,   2019 03 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201902234210263609
  • 米国有害事象自発報告(FAERS)を用いた,タクロリムスとアゾール系抗真菌薬併用時における,拒絶反応のリスクに関する研究, 宇野貴哉, 宇野貴哉, 細見光一, 横山聡, 和田恭一, 寺川伸江, 老田章, 高田充隆, 日本薬学会年会要旨集(CD-ROM), 139年会, 4, 111, 111,   2019 03 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201902275407508438
  • データマイニング手法によるNASHの原因医薬品の探索ならびに自己組織化マップの有用性, 河内正二, 尾松直樹, 細見光一, 高田充隆, 浜口常男, 日本薬学会年会要旨集(CD-ROM), 139年会, 4, 111, 111,   2019 03 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201902283551452412
  • Investigation of simulated patient's attitudes toward physical assessment task, Otori Toru, Inoue Tomomi, Hosomi Koichi, Ishiwata Shunji, Fujimoto Mai, Kitakoji Manabu, Kotake Takeshi, Japanese Journal of Pharmaceutical Education, 2, 0, 181, 186,   2019 01 , 10.24489/jjphe.2017-017, http://id.ndl.go.jp/bib/030041784
    Summary:

    Since the passing of the (guidelines aimed to augment the role of the pharmacists in 2010) pharmacists are required to conduct patient vital checks. As a result, the Pharmaceutical Education Model Core Curriculum require physical assessment (PA) competencies of students. In order to carry out physical assessment task, volunteer subjects need to be recruited and trained to perform the role of simulated patients (SPs). However, to date, there are few investigations into SP attitudes toward PA. The purpose of this study is to conduct a questionnaire to investigate SP attitudes towards PA, and their understanding of the current state of the home medical care system. Responses from the questionnaire show volunteer SPs had little knowledge about PA and the home medical care system. During vital check examinations, SPs were open to having their blood measured but were averse to auscultation. This bias was stronger in woman than men. In terms of future considerations, the questionnaire results suggest volunteer SPs need to be instructed on the benefits of having comprehensive vital check assessments as well as understand the meaning of the role they are asked to play in order to better authenticate the patient/pharmacist relationship. This is particularly important as the performance of vital checks have expanded to become a part of home medical care practices.

  • 臨床に活用される医薬品情報を指向した有害事象自発報告データベースの活用と留意点, 細見光一, 日本医薬品情報学会総会・学術大会講演要旨集, 21回, 92, 92,   2018 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201802229274499735
  • 医療ビッグデータのドラッグリポジショニングへの応用―抗精神病薬と関節リウマチの関連性―, 中川千拓, 細見光一, 高田充隆, 医療薬学フォーラム講演要旨集, 26th, 253,   2018 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201802237210252987
  • レセプトデータベースを用いたIBDと各種薬剤との関連性に関する研究, 下埜綾華, 細見光一, 高田充隆, 医療薬学フォーラム講演要旨集, 26th, 286,   2018 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201802246945669164
  • FAERSを用いた抗凝固薬と骨粗鬆症との関連性の検討, 岩瀬真, 細見光一, 木下佐昌子, 木下佐昌子, 高田充隆, 医療薬学フォーラム講演要旨集, 26th, 253,   2018 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201802255963085723
  • リアルワールドデータを用いた生活習慣病に対するポリファーマシーの実態調査, 森田真央, 細見光一, 丸野なつみ, 馬渕賢幸, 馬渕賢幸, 高田充隆, 医療薬学フォーラム講演要旨集, 26th, 263,   2018 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201802276325032698
  • レセプトデータベースを用いた複数医療機関受診に関する研究, 岡島笑茉, 細見光一, 高田充隆, 医療薬学フォーラム講演要旨集, 26th, 286,   2018 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201802287951073019
  • ボリコナゾールによる有害事象に関する発現時期プロファイルと併用薬の影響の解析―有害事象自発報告データベースを用いて―, 上田ひかる, 細見光一, 高田充隆, 医療薬学フォーラム講演要旨集, 26th, 287,   2018 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201802287976552035
  • リアルワールドデータを活用したポリファーマシーの実態調査, 細見光一, 丸野なつみ, 森田真央, 馬渕賢幸, 馬渕賢幸, 藤本麻依, 高田充隆, 日本薬学会年会要旨集(CD-ROM), 138年会, 4, 172, 172,   2018 03 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201802234412335900
  • Investigation of simulated patient’s attitudes toward physical assessment task, 大鳥徹, 井上知美, 細見光一, 石渡俊二, 藤本麻依, 北小路学, 小竹武, 薬学教育(Web), 2, ROMBUNNO.2017‐017(J‐STAGE),   2018 , 10.24489/jjphe.2017-017, https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201902240389987163
  • 医療情報データベースを用いたポリファーマシーの実態調査, 細見光一, 丸野なつみ, 藤本麻依, 高田充隆, 日本薬剤疫学会学術総会抄録集, 23回, 65, 67,   2017 11 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201702266470572174
  • 医療ビッグデータを活用したポリファーマシーに関する解析―まずは80歳以上での適正化が職能の発揮どころ―, 馬渕賢幸, 馬渕賢幸, 細見光一, 丸野なつみ, 藤本麻依, 村田卓, 高田充隆, 日本薬剤師会学術大会(Web), 50回, [P, 071],   2017 10 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201802255746463305
  • 心疾患患者における薬剤師の今後の役割と課題~フィジカルアセスメント~, 井上知美, 大鳥徹, 細見光一, 石渡俊二, 西田升三, 小竹武, 日本心臓病学会学術集会(Web), 65回, CS4, 2,   2017 09 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201702224726139292
  • 血清アミオダロン及び代謝物濃度と甲状腺機能異常との関連, 大和幹枝, 大和幹枝, 和田恭一, 和田恭一, 林友鴻, 寺川伸江, 川端一功, 藤本麻依, 細見光一, 老田章, 高田充隆, 日本心臓病学会学術集会(Web), 65回, O, 145,   2017 09 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201702265703390563
  • 有害事象自発報告データベースを用いた年齢別でのポリファーマシーの実態調査, 細見光一, 丸野なつみ, 藤本麻依, 高田充隆, 医療薬学フォーラム講演要旨集, 25th, 237,   2017 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201702228684414481
  • 有害事象自発報告データベースを用いた抗リウマチ薬による二次発がんリスクの検討, 橋本夏恵, 細見光一, 藤本麻依, 高田充隆, 日本医薬品情報学会総会・学術大会講演要旨集, 20回, 148, 148,   2017 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201802215181350414
  • 低用量アスピリンと抗潰瘍薬の併用に関する薬剤疫学的研究, 左神慶子, 藤本麻依, 細見光一, 岩澤真紀子, 高田充隆, 日本医薬品情報学会総会・学術大会講演要旨集, 20回, 157, 157,   2017 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201802218279291096
  • 睡眠剤による乳汁分泌障害のプロファイル解析―有害事象自発報告DBを用いて―, 川崎遥, 細見光一, 藤本麻依, 高田充隆, 日本医薬品情報学会総会・学術大会講演要旨集, 20回, 147, 147,   2017 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201802235884657723
  • 有害事象別ポリファーマシーの実態調査―有害事象自発報告データベースを用いて―, 丸野なつみ, 細見光一, 藤本麻依, 高田充隆, 日本医薬品情報学会総会・学術大会講演要旨集, 20回, 147, 147,   2017 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201802242839933331
  • 抗精神病薬服用による脂質異常症のリスクに関する研究, 福嶋恵里, 藤本麻依, 細見光一, 高田充隆, 日本医薬品情報学会総会・学術大会講演要旨集, 20回, 145, 145,   2017 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201802258926105296
  • 非弁膜症性心房細動患者における新規経口抗凝固薬とワルファリンの出血リスクの比較, 田中侑希, 藤本麻依, 中北和樹, 中北和樹, 細見光一, 高田充隆, 日本医薬品情報学会総会・学術大会講演要旨集, 20回, 142, 142,   2017 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201802280823771996
  • CS分析(Customer Satisfaction analysis)による薬剤師のためのフィジカルアセスメント講習会の評価と改善, 大鳥 徹, 井上 知美, 細見 光一, 中川 博之, 高島 敬子, 近藤 尚美, 高田 亜美, 伊藤 栄次, 中山 隆志, 和田 哲幸, 石渡 俊二, 前川 智弘, 船上 仁範, 中村 真也, 窪田 愛恵, 平出 敦, 松山 賢治, 西田 升三, 社会薬学, 35, 2, 94, 101,   2016 12 , 10.14925/jjsp.35.2_94
    Summary:フィジカルアセスメント講習会に参加した143名を対象にアンケートを実施した。CS分析(Customer Satisfaction analysis)とテキストマイニングにより検討した。男性が39%、女性が61%と女性が多かった。勤務先は保険調剤薬局が38%、病院が62%となっており、病院勤務者が多かった。改善度は、数値が大きいほど改善の優先順位は高くなるが、改善度の値が大きい順に五つ項目を上げると、「心電図の読み方」「呼吸音の聴診」「SBAR」「時間は適当でしたか」「心音の聴診」であった。CSグラフにおいて、優先的に改善する必要がある項目がプロットされる「要改善項目」(第4象限)として抽出されてきたのは、「呼吸音の聴診」、「SBAR」であった。「心音・腸音の聴診」、「心電図の読み方」、「血圧測定」は評価が低く、総合評価への影響度も低い項目である「改善検討項目」として第3象限にプロットされた。「講義内容」、「症例に興味が持てたか」、「フィジカルアセスメントモデルの機能」、「時間は適当でしたか」は評点が高く、総合評価への影響度も高い項目である「重要維持項目」として第1象限にプロットされた。
  • 医薬品の安全性および育薬・創薬・基礎研究への活用を指向した副作用報告データベースのシグナルライブラリーの構築, 細見 光一, 浦田 佳奈子, 藤本 麻依, 高田 充隆, 日本薬剤師会学術大会講演要旨集, 49回, P, 082,   2016 10
  • 因子分析による薬剤師と薬学生のフィジカルアセスメントスキル修得に対する特性の比較検討, 大鳥 徹, 中川 博之, 高島 敬子, 近藤 尚美, 高田 亜美, 細見 光一, 井上 知美, 北小路 学, 西田 升三, 松山 賢治, 社会薬学, 35, Suppl., 46, 46,   2016 08
  • 【薬剤疫学〜医療ビッグデータの利活用〜】 ナショナルデータベースを用いた副作用のシグナル検出, 細見 光一, 医薬ジャーナル, 52, 8, 1873, 1879,   2016 08
    Summary:厚生労働省が構築した「レセプト情報・特定健診等情報データベース(ナショナルデータベース)」は,ほぼ全国民のレセプトがデータベース化された状況にある。薬剤による副作用の研究における重要な手法として,レセプトデータベースを用いたSequence symmetry analysis(SSA)の解析が知られている。SSAではPrescription sequence symmetry analysis(PSSA)とEvent sequence symmetry analysis(ESSA)が代表的な手法である。本稿では,ナショナルデータベースを用いたPSSAとESSAによる抗精神病薬(非定型・定型)の錐体外路系症状のシグナル検出について紹介する。自発報告データベースを用いた解析とのMulti-methodological approachにより,副作用に関する情報強化に期待できる。(著者抄録)
  • 薬剤疫学~医療ビッグデータの利活用~5.ナショナルデータベースを用いた副作用のシグナル検出, 細見光一, 医薬ジャーナル, 52, 8, 1873‐1879,   2016 08 01 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201602247654144846
  • レセプトデータを使用したシベンゾリンと低血糖の関連性に関する研究, 橋本明日香, 藤本麻依, 細見光一, 高田充隆, 医療薬学フォーラム講演要旨集, 24th, 192,   2016 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201802224126772491
  • 有害事象自発報告データベースを用いたアルツハイマー型認知症治療薬による有害事象のスクリーニング, 小松唯可, 細見光一, 藤本麻依, 高田充隆, 医療薬学フォーラム講演要旨集, 24th, 191,   2016 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201802236950295783
  • 有害事象自発報告データベースを用いた下部消化管障害の原因薬剤の解析, 中村瑠里, 細見光一, 藤本麻依, 高田充隆, 医療薬学フォーラム講演要旨集, 24th, 191,   2016 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201802240707265359
  • 超高齢化社会を見据えた有害事象発現リスクの解析, 畑中萌花, 細見光一, 藤本麻依, 高田充隆, 医療薬学フォーラム講演要旨集, 24th, 192,   2016 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201802254823576217
  • レセプトデータを用いた強心配糖体製剤の有害事象に関する研究, 杉本泰浩, 藤本麻依, 細見光一, 高田充隆, 医療薬学フォーラム講演要旨集, 24th, 192,   2016 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201802260353356114
  • JMDCレセプトデータを用いたアミオダロンと甲状腺機能障害との関連性に関する研究, 大西佑依, 藤本麻依, 細見光一, 高田充隆, 医療薬学フォーラム講演要旨集, 24th, 192,   2016 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201802287072817399
  • 抗不整脈薬による癌罹患リスクの関連性の解析 有害事象自発報告データベースを用いて, 細見 光一, 保田 彩夏, 藤本 麻依, 高田 充隆, 日本医薬品情報学会総会・学術大会講演要旨集, 19回, 137, 137,   2016 05
  • 抗不整脈薬による癌罹患リスクの関連性の解析:有害事象自発報告データベースを用いて, 細見光一, 保田彩夏, 藤本麻依, 高田充隆, 日本医薬品情報学会総会・学術大会講演要旨集, 19th, 137,   2016 05 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201602291693179232
  • 糖尿病治療薬使用と癌罹患リスクの関連性の解析 有害事象自発報告データベースを用いて, 細見 光一, 浦田 佳奈子, 藤本 麻依, 高田 充隆, 日本薬学会年会要旨集, 136年会, 4, 106, 106,   2016 03
  • Survey on Customer Satisfaction for Evaluation and Improvement of Physical Assessment Practical Training Seminar for Pharmacists, Otori Toru, Wada Tetsuyuki, Ishiwata Shunji, Maegawa Tomohiro, Funakami Yoshinori, Nakamura Shinya, Kubota Yoshie, Hiraide Atsushi, Matsuyama Kenji, Nishida Shozo, Inoue Tomomi, Hosomi Koichi, Nakagawa Hiroyuki, Takashima Keiko, Kondo Hisami, Takada Tsugumi, Ito Eiji, Nakayama Takashi, Japanese Journal of Social Pharmacy, 35, 2, 94, 101,   2016 , 10.14925/jjsp.35.2_94, http://jglobal.jst.go.jp/public/201702220578908674
    Summary:

    In the areas of home medical care and self-medication, the role of the pharmacist is growing, partly as a result of Japan's aging society and the need to reduce medical costs. In response, the Kinki University Faculty of Pharmacy implemented a physical assessment practical training seminar in order to improve the physical assessment skills of practicing pharmacists. A series of questionnaires were conducted among pharmacists to investigate their perceptions of physical assessment practical training seminars. The results of the questionnaires were analyzed using Customer Satisfaction (CS) analysis and text mining. Based on a 5-point scale (1-low∼5-high), questionnaires revealed satisfaction for physical assessment practical training seminars was 4.6±0.6 (Ave.±S.D.). CS analysis revealed that the items "lectures" and "case seminars" had the highest level of satisfaction. However, items showing low levels of satisfaction were "auscultation of respiratory sounds" and "SBAR (Situation, Background, Assessment, Recommendation)." Results of text mining suggested a relationship between "physical assessment" and "difficult". Analysis of the questionnaires showed a high level satisfaction with physical assessment practical training seminars, notably physical assessment practice methods. However, CS analysis and text mining indicate the finer techniques of physical assessment were difficult to acquire.

  • 糖尿病治療薬使用と癌罹患リスクの関連性の解析―有害事象自発報告データベースを用いて―, 細見光一, 浦田佳奈子, 藤本麻依, 高田充隆, 日本薬学会年会要旨集(CD-ROM), 136th, ROMBUNNO.27AB‐AM131,   2016 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201602202294319407
  • 医薬品の安全性および育薬・創薬・基礎研究への活用を指向した副作用報告データベースのシグナルライブラリーの構築, 細見光一, 浦田佳奈子, 藤本麻依, 高田充隆, 日本薬剤師会学術大会(Web), 49th, 405 (WEB ONLY),   2016 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201702230652198414
  • CS分析(Customer Satisfaction analysis)による薬剤師のためのフィジカルアセスメント講習会の評価と改善項目の抽出, 大鳥徹, 井上知美, 細見光一, 伊藤栄次, 中山隆志, 和田哲幸, 石渡俊二, 船上仁範, 中村真也, 平出敦, 窪田愛恵, 松山賢治, 西田升三, 日本医療薬学会年会講演要旨集, 25th, 491,   2015 10 23 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201502203342343919
  • アミオダロン誘発性甲状腺機能異常とアミオダロン及びアミオダロン代謝物血中濃度に関する検討, 大和幹枝, 大和幹枝, 和田恭一, 和田恭一, 粉川俊則, 早川直樹, 安斉俊久, 藤本麻依, 細見光一, 高田充隆, 桑原健, 桑原健, 日本医療薬学会年会講演要旨集, 25th, 225,   2015 10 23 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201502214716850374
  • ダビガトラン及びアピキサバンの出血性合併症に関する比較検討, 向井優太朗, 向井優太朗, 竹中裕美, 内堀聡子, 藤本麻依, 細見光一, 和田恭一, 和田恭一, 粉川俊則, 早川直樹, 桑原健, 桑原健, 高田充隆, 高田充隆, 日本医療薬学会年会講演要旨集, 25th, 224,   2015 10 23 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201502215472766453
  • 有害事象自発報告データベースを用いた抗不整脈薬による有害事象の網羅的解析, 保田 彩夏, 細見 光一, 藤本 麻依, 高田 充隆, 日本医薬品情報学会総会・学術大会講演要旨集, 18回, 125, 125,   2015 06 , 10.11256/jjdi.17.125
  • 有害事象自発報告データベースを用いた抗うつ薬・抗パーキンソン病薬と認知障害の解析, 小西 啓介, 細見 光一, 藤本 麻依, 高田 充隆, 日本医薬品情報学会総会・学術大会講演要旨集, 18回, 125, 125,   2015 06 , 10.11256/jjdi.17.125
  • 大規模医療データベースを用いた抗てんかん薬とがんリスクの関連性に関する研究, 本村 春香, 藤本 麻依, 細見 光一, 高田 充隆, 日本医薬品情報学会総会・学術大会講演要旨集, 18回, 126, 126,   2015 06
  • 大規模医療データベースを用いた各種医薬品と認知症との関連性に関する研究, 森本早矢香, 藤本麻衣, 細見光一, 高田充隆, 医療薬学フォーラム講演要旨集, 23rd, 337,   2015 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201502211205798715
  • 有害事象自発報告データベースを用いたリスクシグナルライブラリーの構築―糖尿病治療薬による有害事象のスクリーニング―, 浦田佳奈子, 細見光一, 藤本麻依, 高田充隆, 医療薬学フォーラム講演要旨集, 23rd, 336,   2015 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201502212265101345
  • 有害事象自発報告データベース解析のドラッグ・リポジショニングへの応用に関する研究―ACE阻害薬およびアンジオテンシン受容体遮断薬と消化管出血との関係―, 赤坂英里加, 藤本麻衣, 細見光一, 高田充隆, 医療薬学フォーラム講演要旨集, 23rd, 337,   2015 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201502215755142120
  • PMDA医薬品副作用データベースを用いた漢方製剤の安全性シグナルの解析, 増井 怜香, 細見 光一, 藤本 麻依, 高田 充隆, 日本薬学会年会要旨集, 135年会, 4, 54, 54,   2015 03
  • 日米の有害事象自発報告データベースを用いた心不全及び浮腫の解析, 乗本 賀世, 細見 光一, 藤本 麻依, 高田 充隆, 日本薬学会年会要旨集, 135年会, 4, 54, 54,   2015 03
  • 高血圧治療薬によるGERDおよび誤嚥性肺炎の解析 日米の有害事象自発報告データベースを用いて, 橋本 雅之, 細見 光一, 藤本 麻依, 高田 充隆, 日本薬学会年会要旨集, 135年会, 4, 54, 54,   2015 03
  • 抗精神病薬使用と錐体外路症状の関連性の解析 ナショナルデータベースを用いて, 細見 光一, 日本薬学会年会要旨集, 135年会, 4, 169, 169,   2015 03
  • 有害事象自発報告データベースを用いた糖尿病薬の有害事象の解析, 浦田 佳奈子, 細見 光一, 藤本 麻依, 高田 充隆, 日本薬学会年会要旨集, 135年会, 4, 169, 169,   2015 03
  • 有害事象自発報告データベースを用いたβ受容体関連薬剤による血中カリウム値への影響の解析, 梅本 晃良, 細見 光一, 藤本 麻依, 高田 充隆, 日本薬学会年会要旨集, 135年会, 4, 169, 169,   2015 03
  • 日米の有害事象自発報告データベースを用いた心不全及び浮腫の解析, 乘本賀世, 細見光一, 藤本麻依, 高田充隆, 日本薬学会年会要旨集(CD-ROM), 135th, ROMBUNNO.27E-PM03S,   2015 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201502231142726077
  • 抗精神病薬使用と錐体外路症状の関連性の解析―ナショナルデータベースを用いて―, 細見光一, 日本薬学会年会要旨集(CD-ROM), 135th, ROMBUNNO.26PB-PM009,   2015 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201502231517959716
  • 高血圧治療薬によるGERDおよび誤嚥性肺炎の解析―日米の有害事象自発報告データベースを用いて―, 橋本雅之, 細見光一, 藤本麻依, 高田充隆, 日本薬学会年会要旨集(CD-ROM), 135th, ROMBUNNO.27E-PM05S,   2015 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201502238735125724
  • 有害事象自発報告データベースを用いたβ受容体関連薬剤による血中カリウム値への影響の解析, 梅本晃良, 細見光一, 藤本麻依, 高田充隆, 日本薬学会年会要旨集(CD-ROM), 135th, ROMBUNNO.26PB-PM011S,   2015 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201502262065098575
  • 有害事象自発報告データベースを用いた糖尿病薬の有害事象の解析, 浦田佳奈子, 細見光一, 藤本麻依, 高田充隆, 日本薬学会年会要旨集(CD-ROM), 135th, ROMBUNNO.26PB-PM010S,   2015 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201502267867686970
  • PMDA医薬品副作用データベースを用いた漢方製剤の安全性シグナルの解析, 増井怜香, 細見光一, 藤本麻依, 高田充隆, 日本薬学会年会要旨集(CD-ROM), 135th, ROMBUNNO.27E-PM01S,   2015 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201502295201651009
  • PMDA医薬品副作用データベースを用いた漢方製剤の安全性シグナルの解析, 細見 光一, 増井 怜香, 藤本 麻依, 高田 充隆, 日本医薬品情報学会総会・学術大会講演要旨集, 17回, 118, 118,   2014 07
  • PMDA医薬品副作用データベースを用いた漢方製剤の安全性シグナルの解析, 細見光一, 増井怜香, 藤本麻依, 高田充隆, 日本医薬品情報学会総会・学術大会講演要旨集, 17th, 118,   2014 07 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201402270364835670
  • スタチン系薬剤による糖尿病発症のリスク―処方せんデータによる解析―, 狩野汀, 藤本麻依, 細見光一, 高田充隆, 医療薬学フォーラム講演要旨集, 22nd, 254,   2014 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201502241547524094
  • PMDA医薬品副作用データベースを用いた安全性シグナルの解析―横紋融解症,悪性症候群,アナフィラキシー反応,スティーブンス・ジョンソン症候群,中毒性表皮壊死症―, 増井怜香, 細見光一, 藤本麻依, 高田充隆, 医療薬学フォーラム講演要旨集, 22nd, 254,   2014 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201502259836273870
  • 処方箋データベースを用いたHMG‐CoA還元酵素阻害薬であるスタチン系薬剤による睡眠障害の解析, 高本真志, 藤本麻依, 細見光一, 高田充隆, 医療薬学フォーラム講演要旨集, 22nd, 253,   2014 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201502263002813378
  • データマイニング手法によるオピオイド受容体鎮痛薬の安全性シグナルの解析―ペンタゾシンと急性膵炎の関連性―, 仁田雅之, 細見光一, 藤本麻依, 高田充隆, 医療薬学フォーラム講演要旨集, 22nd, 254,   2014 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201502263674753209
  • 日米の有害事象自発報告データベースを用いたSMQ分類による有害事象別性差の解析, 乗本賀世, 細見光一, 藤本麻依, 高田充隆, 医療薬学フォーラム講演要旨集, 22nd, 253,   2014 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201502277860988900
  • 処方せんデータを用いたスタチン系薬剤と蓄尿症状の関連性についての研究, 樋口智也, 藤本麻依, 細見光一, 高田充隆, 医療薬学フォーラム講演要旨集, 22nd, 253,   2014 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201502293051844323
  • スタチン系薬剤使用と下部尿路機能障害・睡眠障害の関連性 処方せんデータを用いた解析, 藤本 麻依, 樋口 智也, 高本 真志, 狩野 汀, 細見 光一, 高田 充隆, 日本薬学会年会要旨集, 134年会, 4, 146, 146,   2014 03
  • PMDA医薬品副作用データベース(JADER)を用いた各種安全性シグナルの解析, 細見 光一, 朴 ピナウル, 増井 怜香, 藤本 麻依, 高田 充隆, 日本薬学会年会要旨集, 134年会, 4, 153, 153,   2014 03
  • スタチン系薬剤による蓄尿機能障害の副作用リスクに関する研究, 田村美加子, 藤本麻依, 細見光一, 高田充隆, 生体機能と創薬シンポジウム要旨集, 2014, 160,   2014 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201402201278112400
  • 処方せんデータベースを用いたスタチン系薬剤使用と睡眠障害・うつ症状の関連性について, 高本真志, 藤本麻依, 細見光一, 高田充隆, 生体機能と創薬シンポジウム要旨集, 2014, 162,   2014 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201402212115210717
  • PMDA医薬品副作用データベース(JADER)を用いた各種安全性シグナルの解析, 細見光一, 朴ピナウル, 増井怜香, 藤本麻依, 高田充隆, 日本薬学会年会要旨集(CD-ROM), 134th, ROMBUNNO.30AMM-088,   2014 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201402217468785685
  • スタチン系薬剤使用と下部尿路機能障害・睡眠障害の関連性―処方せんデータを用いた解析―, 藤本麻依, 樋口智也, 高本真志, 狩野汀, 細見光一, 高田充隆, 日本薬学会年会要旨集(CD-ROM), 134th, ROMBUNNO.30AMM-044,   2014 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201402218126410805
  • 各種データベースを用いたスタチン系薬剤と膀胱がんとの関連性についての研究, 樋口智也, 藤本麻依, 細見光一, 高田充隆, 生体機能と創薬シンポジウム要旨集, 2014, 161,   2014 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201402228630175200
  • アンジオテンシンII受容体拮抗薬及びACE阻害薬によるがん発症リスクの検討―データベースを用いた解析―, 狩野汀, 藤本麻依, 細見光一, 高田充隆, 生体機能と創薬シンポジウム要旨集, 2014, 159,   2014 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201402262710849982
  • 日米の有害事象自発報告データベースを用いた厚生労働省の重篤副作用疾患別対応マニュアルの解析, 福田 亜矢, 細見 光一, 藤本 麻依, 高田 充隆, 日本薬剤師会学術大会講演要旨集, 46回, 390, 390,   2013 09
  • 日米の有害事象自発報告データベースを用いたニューキノロン系抗菌薬による有害事象の解析, 新居 万莉, 細見 光一, 藤本 麻依, 高田 充隆, 日本薬剤師会学術大会講演要旨集, 46回, 390, 390,   2013 09
  • 日米の有害事象自発報告データベースを用いた定型及び非定型抗精神病薬による有害事象の解析, 朴 ピナウル, 細見 光一, 豕瀬 諒, 藤本 麻依, 高田 充隆, 日本薬剤師会学術大会講演要旨集, 46回, 391, 391,   2013 09
  • 兵庫県ママサポート薬剤師による地域の子育て支援の実践と課題, 細見 尚子, 下田 幸枝, 細見 光一, 高田 充隆, 日本薬剤師会学術大会講演要旨集, 46回, 517, 517,   2013 09
  • 重篤副作用疾患別対応マニュアルを補完する副作用情報の可視化と解析―日本の有害事象自発報告データベースを用いて―, 細見光一, 福田亜矢, 藤本麻依, 高田充隆, 日本医療薬学会年会講演要旨集, 23rd, 285,   2013 08 28 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201302262668688038
  • 日米の有害事象自発報告データを用いたHMG-CoA還元酵素阻害薬の有害事象の解析, 村上 兆司, 細見 光一, 藤本 麻依, 高田 充隆, 日本医薬品情報学会総会・学術大会講演要旨集, 16回, 102, 102,   2013 08
  • 日米の有害事象自発報告データを用いたβ遮断薬の薬剤選択の指針に対する安全性の検討, 梅本 晃良, 細見 光一, 藤本 麻依, 高田 充隆, 日本医薬品情報学会総会・学術大会講演要旨集, 16回, 103, 103,   2013 08
  • 医薬品副作用被害救済制度の実態把握, 青山 友紀, 細見 光一, 藤本 麻依, 高田 充隆, 日本医薬品情報学会総会・学術大会講演要旨集, 16回, 106, 106,   2013 08
  • 日米の有害事象自発報告データを用いたHMG‐CoA還元酵素阻害薬の有害事象の解析, 村上兆司, 細見光一, 藤本麻依, 高田充隆, 日本医薬品情報学会総会・学術大会講演要旨集, 16th, 102,   2013 08 01 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201302213479941619
  • 医薬品副作用被害救済制度の実態把握, 青山友紀, 細見光一, 藤本麻依, 高田充隆, 日本医薬品情報学会総会・学術大会講演要旨集, 16th, 106,   2013 08 01 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201302213703780944
  • 日米の有害事象自発報告データを用いたβ遮断薬の薬剤選択の指針に対する安全性の検討, 梅本晃良, 細見光一, 藤本麻依, 高田充隆, 日本医薬品情報学会総会・学術大会講演要旨集, 16th, 103,   2013 08 01 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201302274839842136
  • 重篤副作用疾患別対応マニュアルを補完する有害事象自発報告データベースの解析, 細見 光一, 福田 亜矢, 高田 充隆, 日本薬学会年会要旨集, 133年会, 4, 135, 135,   2013 03
  • FDA有害事象自発報告データベースを用いた抗凝固薬による消化器関連事象の比較, 真鍋 彩香, 河内 正二, 井上 和香, 細見 光一, 高田 充隆, 濱口 常男, 日本薬学会年会要旨集, 133年会, 4, 143, 143,   2013 03
  • 加速度センサを用いた調剤技能の動作解析, 松野 純男, 朝倉 南美, 齊藤 美穂, 波部 斉, 細見 光一, 大星 直樹, 高田 充隆, 日本薬学会年会要旨集, 133年会, 4, 240, 240,   2013 03
  • FDA有害事象自発報告データベースを用いた抗凝固薬による消化器関連事象の比較, 真鍋彩香, 河内正二, 井上和香, 細見光一, 高田充隆, 濱口常男, 日本薬学会年会要旨集(CD-ROM), 133rd, ROMBUNNO.29AMF-326S,   2013 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201302217254855433
  • 重篤副作用疾患別対応マニュアルを補完する有害事象自発報告データベースの解析, 細見光一, 福田亜矢, 高田充隆, 日本薬学会年会要旨集(CD-ROM), 133rd, ROMBUNNO.29AMF-279,   2013 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201302252774684313
  • 加速度センサを用いた調剤技能の動作解析, 松野純男, 朝倉南美, 齊藤美穂, 波部斉, 細見光一, 大星直樹, 高田充隆, 日本薬学会年会要旨集(CD-ROM), 133rd, ROMBUNNO.30AMG-127,   2013 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201302297569651384
  • 日米の有害事象自発報告データベースを用いた定型及び非定型抗精神病薬による有害事象の解析, 朴ピナウル, 細見光一, 豕瀬諒, 藤本麻依, 高田充隆, 日本薬剤師会学術大会講演要旨集, 46th, 391,   2013 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201402213684404178
  • 日米の有害事象自発報告データベースを用いた厚生労働省の重篤副作用疾患別対応マニュアルの解析, 福田亜矢, 細見光一, 藤本麻依, 高田充隆, 日本薬剤師会学術大会講演要旨集, 46th, 390,   2013 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201402233882094452
  • 兵庫県ママサポート薬剤師による地域の子育て支援の実践と課題, 細見尚子, 下田幸枝, 細見光一, 高田充隆, 日本薬剤師会学術大会講演要旨集, 46th, 517,   2013 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201402239493098904
  • 日米の有害事象自発報告データベースを用いたニューキノロン系抗菌薬による有害事象の解析, 新居万莉, 細見光一, 藤本麻依, 高田充隆, 日本薬剤師会学術大会講演要旨集, 46th, 390,   2013 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201402244135133963
  • 有害事象自発報告データベースを用いた甲状腺機能異常事象の解析, 細見光一, 福田亜矢, 高田充隆, 日本医療薬学会年会講演要旨集, 22nd, 338,   2012 10 10 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201202216135889890
  • 有害事象自発報告データベースを用いたニューキノロン系抗菌薬とNSAIDsの併用による痙攣事象の解析, 細見 光一, 新居 万莉, 高田 充隆, 日本薬剤師会学術大会講演要旨集, 45回, 415, 415,   2012 10
  • 有害事象自発報告データベースを用いたニューキノロン系抗菌薬とNSAIDsの併用による痙攣事象の解析, 新居万莉, 細見光一, 高田充隆, 日本医薬品情報学会総会・学術大会講演要旨集, 15th, 111,   2012 06 10 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201202210880487592
  • 臨床に活用される医薬品情報を指向した有害事象自発報告データの解析, 細見光一, 日本医薬品情報学会総会・学術大会講演要旨集, 15th, 49,   2012 06 10 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201202237419537451
  • 有害事象自発報告データベースを用いた甲状腺機能異常事象の解析, 福田亜矢, 細見光一, 高田充隆, 日本医薬品情報学会総会・学術大会講演要旨集, 15th, 110,   2012 06 10 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201202247269092362
  • 新たな医薬品情報学研究の構築 医療情報データの解析と医薬品情報 臨床に活用される医薬品情報を指向した有害事象自発報告データの解析, 細見 光一, 日本医薬品情報学会総会・学術大会講演要旨集, 15回, 49, 49,   2012 06
  • 有害事象自発報告データベースを用いた甲状腺機能異常事象の解析, 福田 亜矢, 細見 光一, 高田 充隆, 日本医薬品情報学会総会・学術大会講演要旨集, 15回, 110, 110,   2012 06
  • 有害事象自発報告データベースを用いたニューキノロン系抗菌薬とNSAIDsの併用による痙攣事象の解析, 新居 万莉, 細見 光一, 高田 充隆, 日本医薬品情報学会総会・学術大会講演要旨集, 15回, 111, 111,   2012 06
  • 在宅医療実施による薬剤師の意識変化~テキストマイニングによるあぶり出し~, 李繭香, 堀野智美, 大和幹枝, 高橋直子, 岸田充生, 細見光一, 藤垣哲彦, 松野純男, 北小路学, 高田充隆, 日本薬学会年会要旨集, 132nd, 4, 189,   2012 03 05 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201202209476360637
  • 関節リウマチ治療における生物学的製剤による安全性シグナル指標RORの解析, 細見光一, 豕瀬諒, 朴ピナウル, 高田充隆, 日本薬学会年会要旨集, 132nd, 4, 248,   2012 03 05 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201202255233623089
  • 在宅医療実施による薬剤師の意識変化 テキストマイニングによるあぶり出し, 李 繭香, 堀野 智美, 大和 幹枝, 高橋 直子, 岸田 充生, 細見 光一, 藤垣 哲彦, 松野 純男, 北小路 学, 高田 充隆, 日本薬学会年会要旨集, 132年会, 4, 189, 189,   2012 03
  • 関節リウマチ治療における生物学的製剤による安全性シグナル指標RORの解析, 細見 光一, 豕瀬 諒, 朴 ピナウル, 高田 充隆, 日本薬学会年会要旨集, 132年会, 4, 248, 248,   2012 03
  • 有害事象自発報告データベースを用いたニューキノロン系抗菌薬とNSAIDsの併用による痙攣事象の解析, 細見光一, 新居万莉, 高田充隆, 日本薬剤師会学術大会講演要旨集, 45th, 415,   2012 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201202215437723323
  • アスピリン使用時における医薬品併用による安全性シグナル指標RORの解析, 細見 光一, 炭床 啓太, 宮本 秀彰, 高田 充隆, 日本薬剤疫学会学術総会抄録集, 17回, 58, 59,   2011 11
  • FDA有害事象自発報告データベースを用いた分子標的抗がん剤による肝炎関連有害事象シグナルの解析, 豕瀬諒, 細見光一, 朴ピナウル, 高田充隆, 日本医療薬学会年会講演要旨集, 21st, 289,   2011 09 09 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201102211105627840
  • 調剤過誤シナリオを使用した模擬患者対応ロールプレイ実習―アドバンスコミュニケーション学習―, 小竹武, 細見光一, 大鳥徹, 井上知美, 安原智久, 北小路学, 船上仁範, 谷野公俊, 村上悦子, 八軒浩子, 高田充隆, 松山賢治, 日本医療薬学会年会講演要旨集, 21st, 386,   2011 09 09 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201102228364764716
  • FDA有害事象自発報告データベースを用いた抗精神病薬による有害事象シグナルの解析, 朴ピナウル, 細見光一, 豕瀬諒, 高田充隆, 日本医療薬学会年会講演要旨集, 21st, 288,   2011 09 09 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201102237724767257
  • 有害事象自発報告データベースを用いた医薬品併用による定量的シグナル指標の解析, 炭床啓太, 細見光一, 宮本秀彰, 高田充隆, 日本医療薬学会年会講演要旨集, 21st, 288,   2011 09 09 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201102264707924427
  • 在宅医療へ薬剤師が参画するための問題解決策の探索及び提案, 李繭香, 堀野智美, 大和幹枝, 山村万里子, 高橋直子, 北小路学, 細見光一, 岸田充生, 近藤直緒美, 菅濱淳仁, 乾英夫, 藤垣哲彦, 松野純男, 高田充隆, 日本医療薬学会年会講演要旨集, 21st, 371,   2011 09 09 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201102272899898044
  • 6年制長期実務実習第1期に関する学生アンケート調査:Customer Satisfaction(CS)分析により抽出された改善項目, 村上悦子, 大鳥徹, 高田充隆, 小竹武, 細見光一, 北小路学, 井上知美, 八軒浩子, 松山賢治, 日本薬学会年会要旨集, 131st, 4, 360,   2011 03 05 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201102200185927422
  • 薬局薬剤師の在宅医療への参画の現状~主要な問題点の抽出とその原因の解析~, 李繭香, 北小路学, 岸田充生, 高橋直子, 細見光一, 松野純男, 高田充隆, 日本薬学会年会要旨集, 131st, 4, 274,   2011 03 05 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201102265531917808
  • アスピリンによる消化管障害はレニン・アンジオテンシン系阻害薬によって抑制されるのか―FDA大規模有害事象自発報告(AERS)の解析から―, 炭床啓太, 細見光一, 宮本秀彰, 高田充隆, 日本薬学会年会要旨集, 131st, 4, 261,   2011 03 05 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201102279538710924
  • 患者から訴えが出やすい有害事象と起因薬剤は何か?―FDA大規模有害事象自発報告(AERS)の解析から―, 細見光一, 炭床啓太, 宮本秀彰, 高田充隆, 日本薬学会年会要旨集, 131st, 4, 261,   2011 03 05 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201102299608117801
  • アスピリンによる消化管障害はレニン・アンジオテンシン系阻害薬によって抑制されるのか FDA大規模有害事象自発報告(AERS)の解析から, 炭床 啓太, 細見 光一, 宮本 秀彰, 高田 充隆, 日本薬学会年会要旨集, 131年会, 4, 261, 261,   2011 03
  • 患者から訴えが出やすい有害事象と起因薬剤は何か? FDA大規模有害事象自発報告(AERS)の解析から, 細見 光一, 炭床 啓太, 宮本 秀彰, 高田 充隆, 日本薬学会年会要旨集, 131年会, 4, 261, 261,   2011 03
  • 薬局薬剤師の在宅医療への参画の現状 主要な問題点の抽出とその原因の解析, 李 繭香, 北小路 学, 岸田 充生, 高橋 直子, 細見 光一, 松野 純男, 高田 充隆, 日本薬学会年会要旨集, 131年会, 4, 274, 274,   2011 03
  • 6年制長期実務実習第1期に関する学生アンケート調査 Customer Satisfaction(CS)分析により抽出された改善項目, 村上 悦子, 大鳥 徹, 高田 充隆, 小竹 武, 細見 光一, 北小路 学, 井上 知美, 八軒 浩子, 松山 賢治, 日本薬学会年会要旨集, 131年会, 4, 360, 360,   2011 03
  • アスピリン使用時における医薬品併用による安全性シグナル指標RORの解析, 細見光一, 炭床啓太, 宮本秀彰, 高田充隆, 日本薬剤疫学会学術総会抄録集, 17th, 58, 59,   2011 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201202212578122030
  • FDA大規模有害事象自発報告(AERS)を用いた抗血小板薬の有害事象症例の解析, 細見光一, 炭床啓太, 宮本秀彰, 高田充隆, 日本医療薬学会年会講演要旨集, 20th, 303,   2010 10 25 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201002274695218589
  • テキストマイニング手法による医療薬学研究トレンド解析, 後藤佐昌子, 八軒浩子, 細見光一, 北小路学, 高田充隆, 医療薬学フォーラム講演要旨集, 18th, 131,   2010 07 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201002285838274193
  • 薬に対する不安が強い癌患者への薬剤師の役割 麻薬を拒否した3症例を通して, 奥野 昌宏, 高柳 信子, 細見 光一, 梅谷 義晴, 磯部 昌憲, 高宮 靜男, 心身医学, 50, 6, 584, 584,   2010 06
  • 薬に対する不安が強い癌患者への薬剤師の役割 抗癌剤治療を行った骨髄移植予定の2症例を通して, 高柳 信子, 奥野 昌宏, 細見 光一, 梅谷 義晴, 磯部 昌憲, 高宮 靜男, 高蓋 寿郎, 心身医学, 50, 6, 585, 585,   2010 06
  • 薬に対する不安が強い癌患者への薬剤師の役割(1)―麻薬を拒否した3症例を通して―, 奥野昌宏, 高柳信子, 細見光一, 梅谷義晴, 磯部昌憲, 高宮靜男, 心身医学, 50, 6, 584, 584,   2010 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201002225027172592
  • 薬に対する不安が強い癌患者への薬剤師の役割(2)―抗癌剤治療を行った骨髄移植予定の2症例を通して―, 高柳信子, 奥野昌宏, 細見光一, 梅谷義晴, 磯部昌憲, 高宮靜男, 高蓋寿郎, 心身医学, 50, 6, 585, 585,   2010 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=201002241916905157
  • 抗癌剤に対して不安が強い患者への薬剤指導骨髄移植予定の2症例を通して, 高柳信子, 奥野昌宏, 細見光一, 中田学, 梅谷義晴, 高宮静男, 高蓋寿郎, 日本医療薬学会年会講演要旨集, 19th, 260,   2009 09 15 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902239664915434
  • 薬剤師による服用歴確認で酸化マグネシウムの副作用である腸石症の確定診断に結びついた1症例, 久保嘉靖, 奥野昌宏, 中田学, 細見光一, 吉岡正博, 三村純, 小森英司, 梅谷義晴, 日本医療薬学会年会講演要旨集, 19th, 258,   2009 09 15 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902270602659134
  • 広汎性発達障害の患者に対するがん化学療法の薬剤指導のあり方, 奥野 昌宏, 細見 光一, 中田 学, 梅谷 義晴, 高宮 静男, 高蓋 寿郎, 心身医学, 49, 6, 648, 648,   2009 06
  • 抗がん剤無菌調製時における感染対策の現状についての報告, 大東芳子, 権藤直人, 橋田亨, 中浴伸二, 林三千雄, 坂本悦子, 岡田裕, 藤井宏, 俣木陽子, 小林佑子, 山本剛, 熊木まゆ子, 細見光一, 庄司知世, 日本環境感染学会誌, 24, Supplement, 253,   2009 01 13 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902282878184502
  • NST新聞の発刊の意義 NST広報の役割を通して, 奥野 昌宏, 宮崎 純子, 藤本 麻依, 高柳 信子, 佐藤 智子, 中田 学, 細見 光一, 静脈経腸栄養, 24, 1, 404, 404,   2009 01
  • 抗がん剤無菌調製時における感染対策の現状についての報告, 大東 芳子, 権藤 直人, 橋田 亨, 中浴 伸二, 林 三千雄, 坂本 悦子, 岡田 裕, 藤井 宏, 俣木 陽子, 小林 佑子, 山本 剛, 熊木 まゆ子, 細見 光一, 庄司 知世, 日本環境感染学会誌, 24, Suppl., 253, 253,   2009 01
  • NST新聞の発刊の意義~NST広報の役割を通して~, 奥野昌宏, 宮崎純子, 藤本麻依, 高柳信子, 佐藤智子, 中田学, 細見光一, 静脈経腸栄養, 24, 1, 404,   2009 01 01 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902254561089918
  • 外科でのNST回診における薬剤師の役割~短腸症候群の2例を通して~, 宮崎純子, 奥野昌宏, 藤本麻依, 佐藤智子, 中田学, 細見光一, 梅谷義晴, 日本医療薬学会年会講演要旨集, 18th, 261,   2008 09 01 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902219643501337
  • 薬剤師によるNST新聞の発刊の意義―NST広報の役割を通して―, 奥野昌宏, 宮崎純子, 藤本麻依, 高柳信子, 佐藤智子, 中田学, 細見光一, 梅谷義晴, 日本医療薬学会年会講演要旨集, 18th, 261,   2008 09 01 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902282206757270
  • がん化学療法への薬剤師の関わり―がん化学療法の投与中止理由の解析―, 細見光一, 妹川信一, 山崎貴之, 鈴岡広恵, 橋本勝, 日本薬学会年会要旨集, 128th, 4, 186,   2008 03 05 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902259369328382
  • がん化学療法への薬剤師の関わり がん化学療法の投与中止理由の解析, 細見 光一, 妹川 信一, 山崎 貴之, 鈴岡 広恵, 橋本 勝, 日本薬学会年会要旨集, 128年会, 4, 186, 186,   2008 03
  • NST薬剤師の役割~回診時の情報提供を通して~, 佐藤智子, 奥野昌宏, 宮崎純子, 藤本麻依, 高柳信子, 細見光一, 橋本勝, 大西伸策, 静脈経腸栄養, 23, 243,   2008 01 15 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902277834381862
  • NST薬剤師の役割 回診時の情報提供を通して, 佐藤 智子, 奥野 昌宏, 宮崎 純子, 藤本 麻依, 高柳 信子, 細見 光一, 橋本 勝, 大西 伸策, 静脈経腸栄養, 23, 増刊, 243, 243,   2008 01
  • 効率的な調剤業務をめざして 全自動散薬分包機135包型の有用性の検討, 細見 光一, 亀本 みの子, 久保 知子, 藤井 延子, 橋本 勝, 大西 伸策, 日本薬剤師会学術大会講演要旨集, 40回, 543, 543,   2007 10
  • 病院実務研修で得た医療を考える力―調剤支援システムを活用した注射薬調製業務の効率化―, 上田浩貴, 細見光一, 田村理絵, 妹川信一, 山崎貴之, 家村恵, 宮崎純子, 佐藤智子, 久保知子, 藤本麻依, 鈴岡広恵, 村山慶, 向井孝介, 岩川精吾, 橋本勝, 大西伸策, 日本薬学会年会要旨集, 127th, 3, 139,   2007 03 05 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902261203358083
  • 病院実務研修(大学院医療薬学コース)で得た医療を考える力一妊婦・授乳婦の薬のサポートをめざして―, 田村理絵, 細見光一, 上田浩貴, 佐藤智子, 久保嘉靖, 藤本麻依, 中田学, 橋本勝, 岩川精吾, 大西伸策, 日本薬学会年会要旨集, 127th, 3, 189,   2007 03 05 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902262358517893
  • 病院実務研修で得た医療を考える力 調剤支援システムを活用した注射薬調製業務の効率化, 上田 浩貴, 細見 光一, 田村 理絵, 妹川 信一, 山崎 貴之, 家村 恵, 宮崎 純子, 佐藤 智子, 久保 知子, 藤本 麻依, 鈴岡 広恵, 村山 慶, 向井 孝介, 岩川 精吾, 橋本 勝, 大西 伸策, 日本薬学会年会要旨集, 127年会, 3, 139, 139,   2007 03
  • 病院実務研修(大学院医療薬学コース)で得た医療を考える力 妊婦・授乳婦の薬のサポートをめざして, 田村 理絵, 細見 光一, 上田 浩貴, 佐藤 智子, 久保 嘉靖, 藤本 麻依, 中田 学, 橋本 勝, 岩川 精吾, 大西 伸策, 日本薬学会年会要旨集, 127年会, 3, 189, 189,   2007 03
  • NST回診時における薬剤師の役割―当院作成「NST薬剤師回診マニュアル」を通して―, 奥野昌宏, 高柳信子, 橋本勝, 細見光一, 大西伸策, 松本美穂, 高宮静男, 井谷智尚, 京極高久, 草野仁, 静脈経腸栄養, 22, 472,   2007 01 15 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902263035744242
  • NST回診時における薬剤師の役割 当院作成「NST薬剤師回診マニュアル」を通して, 奥野 昌宏, 高柳 信子, 橋本 勝, 細見 光一, 大西 伸策, 松本 美穂, 高宮 静男, 井谷 智尚, 京極 高久, 草野 仁, 静脈経腸栄養, 22, 増刊, 472, 472,   2007 01
  • 効率的な調剤業務をめざして‐全自動散薬分包機135包型の有用性の検討‐, 細見光一, 亀本みの子, 久保知子, 藤井延子, 橋本勝, 大西伸策, 日本薬剤師会学術大会講演要旨集, 40th, 543,   2007 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902253532423039
  • 当院の外来がん化学療法におけるFOLFOX療法の現状調査~薬剤師のがん化学療法への積極的な参加に向けて~, 久保嘉靖, 細見光一, 妹川信一, 家村恵, 佐藤智子, 久保知子, 宮崎純子, 藤本麻依, 橋本勝, 長谷川寛, 奥野敏隆, 京極高久, 林雅造, 井谷智尚, 三村純, 猪熊哲朗, 福田真由美, 大西伸策, 日本癌治療学会誌, 41, 2, 850,   2006 09 04 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902274749989763
  • 当院の外来がん化学療法におけるFOLFOX療法の現状調査 薬剤師のがん化学療法への積極的な参加に向けて, 久保 嘉靖, 細見 光一, 妹川 信一, 家村 恵, 佐藤 智子, 久保 知子, 宮崎 純子, 藤本 麻依, 橋本 勝, 長谷川 寛, 奥野 敏隆, 京極 高久, 林 雅造, 井谷 智尚, 三村 純, 猪熊 哲朗, 福田 真由美, 大西 伸策, 日本癌治療学会誌, 41, 2, 850, 850,   2006 09
  • NST回診時における薬剤師の役割―当院作成「NST薬剤師回診マニュアル」を通して―, 奥野昌宏, 高柳信子, 橋本勝, 細見光一, 大西伸策, 松本美穂, 高宮静男, 井谷智尚, 京極高久, 草野仁, 日本医療薬学会年会講演要旨集, 16th, 325,   2006 09 01 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902207067642592
  • 薬剤師による注射薬調製業務の経済性を考える―外来がん化学療法への薬剤師の関わりから―, 細見光一, 藤本麻依, 妹川信一, 家村恵, 久保嘉靖, 宮崎純子, 佐藤智子, 久保知子, 橋本勝, 大西伸策, 日本医療薬学会年会講演要旨集, 16th, 474,   2006 09 01 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902263548090680
  • 薬剤師による注射薬調製業務の経済性を考える―外来がん化学療法における薬剤師業務の展開から―, 藤本麻依, 細見光一, 妹川信一, 家村恵, 久保嘉靖, 宮崎純子, 佐藤智子, 久保知子, 橋本勝, 大西伸策, 医療薬学フォーラム講演要旨集, 14th, 263,   2006 07 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902292951809759
  • 病院実務実習(大学院医療薬学コース)で得た医療を考える力‐注射薬調剤業務におけるリスクマネジメントへの取り組み‐, 塩野州平, 細見光一, 家村恵, 久保嘉靖, 妹川信一, 宮崎純子, 佐藤智子, 久保知子, 藤本麻依, 橋本勝, 津田泰男, 太田光よし, 大西伸策, 日本薬学会年会要旨集, 126th, 3, 221,   2006 03 06 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902275303159321
  • 病院実務実習(大学院医療薬学コース)で得た医療を考える力 注射薬調剤業務におけるリスクマネジメントへの取り組み, 塩野 州平, 細見 光一, 家村 恵, 久保 嘉靖, 妹川 信一, 宮崎 純子, 佐藤 智子, 久保 知子, 藤本 麻依, 橋本 勝, 津田 泰男, 太田 光煕, 大西 伸策, 日本薬学会年会要旨集, 126年会, 3, 221, 221,   2006 03
  • 注射薬調剤支援システムはどこまで有効活用できるのか, 宮崎純子, 細見光一, 妹川信一, 久保嘉靖, 津田泰男, 大西伸策, 日本医療薬学会年会講演要旨集, 15th, 291,   2005 09 01 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902266350354206
  • Examination of preservative in the eye drop. Comparison between original drug and generic drug., 久保嘉靖, 細見光一, 奥野昌宏, 神代知子, 橋本勝, 顕谷昭久, 平井みどり, 医薬ジャーナル, 41, 1, 117, 125,   2005 01 , http://jglobal.jst.go.jp/public/200902270297934162
    Summary:後発医薬品の点眼薬は,承認申請時に生物学的同等性は求められるが,添加剤に関しては法的規格を満たせば良く,先発医薬品と後発医薬品によっては添加剤が異なる可能性がある.点眼薬の添加剤のうち,保存剤は,種類によって眼刺激などの副作用が報告されており,生体に及ぼす影響は無視できない.我々は,西神戸医療センター採用の点眼薬と,その後発医薬品の保存剤,および保存剤の相違による副作用頻度について調査した.その結果,先発医薬品と後発医薬品で保存剤の異なるものがあった.点眼薬の保存剤として使用されているもののうち,塩化ベンザルコニウムには眼障害の副作用が報告されており,パラオキシ安息香酸エステル類は,温度が低下することによって保存効果が低下することが知られている.点眼薬において,後発医薬品の採用,一般名による調剤および服薬指導の際,有効成分のみならず保存剤の性質も考慮する必要がある(著者抄録)
  • ギモン解決Q&A CAGやPTCAで抗血栓薬を飲むのを禁じたり許可したりしますが,どのような基準で行われていますか?, 細見 光一, Expert Nurse, 20, 13, 10, 11,   2004 11
  • 新薬情報入手に関するアンケート調査, 清原義史, 前田温, 大川恭子, 細見光一, 平野泰健, 河本由紀子, 大西憲明, 平井みどり, 松山賢治, 日本医療薬学会年会講演要旨集, 14th, 322,   2004 09 01 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902202272003002
  • 注射薬自動払出し装置導入による評価と課題, 宮崎純子, 細見光一, 妹川信一, 久保嘉靖, 津田泰男, 大西伸策, 日本医療薬学会年会講演要旨集, 14th, 271,   2004 09 01 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902232248693797
  • 薬・薬・学連携をめざした勉強会(神戸薬学ネットワーク)の取り組み, 金啓二, 西田英之, 東和夫, 池田りき子, 大川恭子, 魚本智子, 小野達也, 河本由紀子, 清原義史, 沢崎高志, 細見光一, 室井延之, 大野真理子, 緒方園子, 大西憲明, 福島昭二, 徳山尚吾, 平井みどり, 松山賢治, 日本医療薬学会年会講演要旨集, 14th, 371,   2004 09 01 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902240648768985
  • Multidisciplinary Psychosocial Support for Pediatric Patients with Cancer and Their Families, Takamiya Shizuo, Hosomi Kouichi, Okumura Tomoko, Matsumoto Miho, Takahara Yukiko, Yamamoto Kinya, Sato Tomoaki, Baba Kunizo, Matsubara Kousaku, Kawamoto Tomo, Shirakawa Keiko, Ido Rika, Sasai Keiko, Tsukioka Mariko, Yonenaga Chika, Okuno Akihiro, Japanese Journal of Psychosomatic Medicine, 44, 1, 51, 59,   2004 01 , 10.15064/jjpm.44.1_51, http://id.ndl.go.jp/bib/6812619
    Summary:Objective : This study investigated the significance of the multidisciplmary psychosocial support for pediatnc patients with cancer and their families Method : Patient's adjustment disorder, mother's post traumatic stress reaction (PTSR), and the other psychosocial problems were examined on 7 mpatients with cancer (5 : acute lymphoblastic leukemia, 2 : malignant lymphoma) admitted to pediatric ward of Nishi-Kobe Medical Center from September, 1998 to March, 2002 Practical details of the multidisciplmary psychosocial support were shown in one patient Results : Patient's adjustment disorder ranked severe for one patient, moderate for two and mild for four These disorders recovered during hospitahzation in all patients except one As for the severity of mother's PTSR, one mother was diagnosed as severe, four as moderate and two as mild Their PTSR recovered within one month The severity of mother's PTSR was well correlated with that of patient's adjustment disorder Conclusions : The multidisciplmary psychosocial support was effective for psychosocial support to pediatric patients with cancer and their families from the viewpoint of team approach, adjustment disorder, PTSR and narrative based medicine
  • 学生実習の受け入れをどう考えていくべきか, 細見光一, 室井延之, 東和夫, 池田りき子, 魚本智子, 大川恭子, 笠井真二, 河本由紀子, 清原義史, 日本薬剤師会学術大会講演要旨集, 36th, 251,   2003 10 12 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902221189992120
  • 点眼剤における保存剤の検討~先発医薬品と後発医薬品の比較~, 久保嘉靖, 細見光一, 奥野昌宏, 神代知子, 橋本勝, 顕谷昭久, 平井みどり, 日本医療薬学会年会講演要旨集, 13th, 268,   2003 09 01 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902266704777622
  • 多施設合同輸液セミナーを実施して―兵庫県病院薬剤師会西神戸支部の試み―, 細見光一, 清原義史, 金啓二, 顕谷昭久, 酒井洋, 三野暁子, 加納久子, 前田温, 日本医療薬学会年会講演要旨集, 13th, 279,   2003 09 01 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902291189939384
  • The Role of the Pharmacist in Integrated Treatment for Pediatric Patients with Eating Disorder, Okuno Akihiro, Hosomi Kouichi, Maekawa Megumi, Takamiya Shizuo, Harigaya Hidekazu, Umetani Yoshiharu, Araya Teruhisa, Takase Nobuaki, Japanese Journal of Psychosomatic Medicine, 42, 7, 450, 458,   2002 07 , 10.15064/jjpm.42.7_449, http://id.ndl.go.jp/bib/6200890
    Summary:A variety of medicines, such as digestive medicines in addition to psychotropic drugs including anxiolytics, antidepressants, hypnotics, antipsychotropic drugs and mania state medical treatment agents may be prescribed to the patients with eating disorder. We observed from the pharmacist's view "Regarding the anxiety about medicine" in the pediatric patients with eating disorder through pharmaceutical care, and examined the role of the pharmacist as a member of therapeutic team for eating disorder. Very important roles of the pharmacist are as in the following: 1. Finding out complaints about medicines by listening to patients 2. Informing patients of "mutual understanding of the anxiety about medicine". 3. Making patients aware of "a pharmacist is always with you" and creating an environment under which patients can take medicines despite anxiety. These trials are good factors to strengthen their ability for self-expression.
  • 化学療法中視力低下を伴った患者に対する薬剤指導, 細見 光一, 奥野 昌宏, 前川 恵, 梅谷 義晴, 津田 泰男, 大西 伸策, 顕谷 昭久, 新里 偉咲, 高宮 静男, 心身医学, 42, 6, 394, 395,   2002 06
  • The Role of Pharmaceutical Care for the Parents with Children Receiving Chemotherapy for Leukemia : Through Pharmaceutical Care for Two Cases of Acute Lymphocytic Leukemia, OKUNO Akihiro, HOSOMI Kouichi, MAEKAWA Megumi, UMETANI Yoshiharu, ARAYA Teruhisa, YAMAMOTO Kinya, TAKAMIYA Shizuo, SATO Tomoaki, MATSUBARA Kousaku, BABA Kunizo, 子どもの心とからだ, 11, 1, 35, 40,   2002 06 , http://jglobal.jst.go.jp/public/200902151684815431
    Summary:症例1(4歳男児).母親は病気を受容しきれず化学療法に対する理解も得られなかった.症例2(6歳女児).母親は副作用の重篤さや患児の服薬困難のために不安が増大していった.薬剤師は聞き手にまわり,不安を共感した上で,仲間がいること,目標が見えるようにすること,褒めながら母親を手伝う薬剤指導により,治療を受け入れる環境が整い,治療を最後まで円滑に進めることができた.また,薬剤指導中に得られた他職種に関係する情報を各チーム医療スタッフに伝達し,連携して対応することで,母親の信頼が生れ,癌化学療法に対する信頼にも繋がった
  • フェノチアジン系薬剤と金属含有薬剤の配合変化, 細見光一, 奥野昌宏, 梅谷義晴, 顕谷昭久, 松山賢治, 萩中淳, 御船正樹, 斎藤寛, 日本薬学会年会要旨集, 122nd, 4, 116,   2002 03 05 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902140665231362
  • フェノチアジン系薬剤と金属含有薬剤の配合変化, 細見 光一, 奥野 昌宏, 梅谷 義晴, 顕谷 昭久, 松山 賢治, 萩中 淳, 御舩 正樹, 斎藤 寛, 日本薬学会年会要旨集, 122年会, 4, 116, 116,   2002 03
  • 見える薬剤師を目指して 職種間チーム医療勉強会を実施して得たもの, 細見光一, 奥野昌宏, 前川恵, 藤井延子, 亀本みの子, 佐藤智子, 大西伸策, 顕谷昭久, 藤堂彰男, 日本病院薬剤師会雑誌, 37, 10, 1321, 1323,   2001 10 , http://jglobal.jst.go.jp/public/200902141992601196
  • A case of localized primary sclerosing cholangitis mimicking intrahepatic bile duct cancer, KAWASAKI Toshihiko, UEO Taro, ITANI Toshinao, SHIBATOHGE Mitsushige, MIMURA Jun, KOMORI Hideshi, TODA Akio, OKUNO Toshitaka, KUDO Masatoshi, Hepatol Res, 20, 2, 259, 264,   2001 06 01 , http://ci.nii.ac.jp/naid/10009900458
    Summary:A 75-year-old woman with chronic hepatitis was regularly followed-up in our hospital. A computed tomography (CT) scan revealed an obviously enlarged intrahepatic bile duct in the posterior branch of the left lateral segment. Percutaneous cholangiography revealed an enlarged posterior branch of the left lateral segment and a narrow stenotic region at the root of this branch. We diagnosed her as having intrahepatic bile duct cancer, and a left lateral segmentectomy of the liver was performed. However, microscopic examination of the resected specimens revealed peribiliary fibrosis in the stenotic bile duct and other areas of the intrahepatic bile duct with no malignant cells. Thus, the final diagnosis was made to be primary sclerosing cholangitis. We must consider primary sclerosing cholangitis in the differential diagnosis of localized stenosis of the intrahepatic bile duct. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
  • Budd-Chiari syndrome and extrahepatic portal obstruction associated with congenital antithrombin III deficiency, NAKASE Hiroshi, KAWASAKI Toshihiko, ITANI Toshinao, MIMURA Jun, KOMORI Hideshi, OKAZAKI Kazuichi, CHIBA Tsutomu, 36, 5, 341, 345,   2001 05 01 , http://ci.nii.ac.jp/naid/10008551654
    Summary:We report a patient with Budd-Chiari syndrome (BCS) and extrahepatic portal obstruction (EHO) associated with congenital antithrombin (AT) III deficiency. A 35-year-old man was admitted to Nishi Kobe Medical Center for evaluation of abnormal intrahepatic veins. By various imaging modalities, BCS and EHO were diagnosed. Laboratory data revealed parallel decreases in activity and antigen concentration of AT III despite normal liver function. Taken together, the etiology of both BCS and EHO was considered to be thrombosis, associated with congenital AT III deficiency. Two years after beginning warfarin therapy, the patient has no symptoms and his liver function remains normal. Anticoagulant therapy is considered useful for preventing progression of the disease.
  • 小児がん化学療法に対する親への薬剤指導 急性リンパ性白血病の2症例を通して, 奥野 昌宏, 細見 光一, 前川 恵, 佐藤 智子, 梅谷 義晴, 顕谷 昭久, 山本 欣哉, 高宮 静男, 佐藤 倫明, 針谷 秀和, 日本児童青年精神医学会総会抄録集, 41回, 126, 126,   2000 10
  • Rolea of drug guidance on treatment of human immunodeficiency virus (HIV) infectious disease., 奥野昌宏, 細見光一, 前川恵, 佐藤智子, 梅谷義晴, 鶴田聡, 医薬ジャーナル, 36, 10, 2844, 2848,   2000 10 , http://jglobal.jst.go.jp/public/200902148850603498
    Summary:ヒト免疫不全ウイルス(HIV)に感染し,すでにエイズを発症している症例へのチーム医療に加わり,薬剤指導の中心を担う薬剤師の役割について検討を行った.この結果,1)食事摂取量を低下させずに,日和見感染予防を重視しながら患者の抗HIV薬の長期の服用を支えること,2)患者は抗HIV薬の服用のみに固守しがちになると予想されるので,生活環境や他の処方薬全てにバランス良く注意を向かせるために,総括的に指導していくこと,の2点が重要と考察された.そして,これらの役割が,HIV感染症治療のチーム医療の中での薬剤師へのニーズであると思われた
  • 薬物療法を拒否する患児・親に対しての薬剤指導 14歳摂食障害と13歳ネフローゼ症候群の症例を通して, 奥野昌宏, 細見光一, 前川恵, 佐藤智子, 梅谷義晴, 顕谷昭久, 針谷秀和, 仁紙宏之, 佐藤倫明, 日本病院薬学会年会講演要旨集, 10, 0, 122, 122,   2000 , 10.20825/jsphcsyaku.10.0_122_2, https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902152801036275
  • Endoscopic Resection of Small Inflammatory Fibroid Polyp of the Colon, NAKASE Hiroshi, MIMURA Jun, KAWASAKI Toshihiko, ITANI Toshinao, KOMORI Hideshi, HASHIMOTO Kimio, OKAZAKI Kazuichi, CHIBA Tsutomu, Internal Medicine, 39, 1, 25, 27,   2000 01 01 , 10.2169/internalmedicine.39.25, http://id.ndl.go.jp/bib/4965379
    Summary:Inflammatory fibroid polyp (IFP) is a solitary intestinal lesion of unknown etiology. Although IFF is benign, laparotomy for the resection of colonic IFP is performed in most cases because the polyp is usually large. We report a successful endoscopic resection of cecal IFP. It is considered that colonic IFP should be resected endoscopically if the polyp is small and is located submucosally.
    (Internal Medicine 39: 25-27, 2000)
  • Colonic Ulceration Caused by Administration of Loxoprofen Sodium, NAKASE Hiroshi, ITANI Toshinao, MIMURA Jun, KAWASAKI Toshihiko, KOMORI Hideshi, HASHIMOTO Kimio, CHIBA Tsutomu, Internal Medicine, 38, 3, 249, 251,   1999 03 , 10.2169/internalmedicine.38.249, http://id.ndl.go.jp/bib/4714754
    Summary:A 54-year-old female with chronic headache was admitted to our hospital because of hematochezia. She had routinely taken loxoprofen sodium because of severe headache. Emergent colonoscopic examination revealed ulceration of the cecum. After administration of loxoprofen sodium was discontinued and administration of sulfasalazine was initiated, her intestinal bleeding subsided. Two months after discontinuation of loxoprofen sodium, the colonoscopic examination revealed scar formation at the site of cecal ulceration. In this case, it was conceivable that the administration of loxoprofen sodium might have induced colonic ulceration.
    (Internal Medicine 38: 249-251, 1999)
  • An Improved Asymmetric Nitroolefination of .ALPHA.-Alkyl-.GAMMA.-and .DELTA.-lactones with Modified Nitroenamines and Its Application to the Synthesis of (-)-Aphanorphine., 野出学, 黒崎竜一, 細見光一, 今里均, 井上武久, 西出喜代治, 反応と合成の進歩シンポジウム講演要旨集, 20th, 201, 205,   1994 10 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902196470272914
  • Preparation of Chiral Bicyclo 3.3.0 octanes by Enzymatic Methods and Their Application to the Natural Products Syntheses., 井上武久, 荒木守, 細見光一, 岡本健, 野出学, 天然有機化合物討論会講演要旨集, 36th, 250, 257,   1994 09 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902178954593555
  • Using Moire Fringes an Absolute Linear Scale With High Resolution and Long Stroke., 細見光一, 新井泰彦, 横関俊介, 山田朝治, 日本機械学会関西支部定時総会講演会講演論文集, 69th, Pt 1, 141, 143,   1994 03 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902116782800019
  • 33 Preparation of Chiral Bicyclo[3.3.0]octanes by Enzymatic Methods and Their Application to the Natural Products Syntheses, Inoue T., Araki M., Hosomi K., Okamoto K., Node M., Symposium on the Chemistry of Natural Products, symposium papers, 36, 0, 250, 257,   1994 , 10.24496/tennenyuki.36.0_250, http://ci.nii.ac.jp/naid/110006679298
    Summary:Chiral bicyclo[3.3.0]octane derivatives 1 are useful as chiral synthons for efficient synthesis of cyclic natural products. Here we describe the asymmetric transformation using enzymatic method of δ-symmetric bicyclic diketones 2a-c and tetraester 9, and the application of chiral bicyclo[3.3.0]octane derivatives [(+)-3b, (+)- and (-)-11] to natural products syntheses. 1. Baker's yeast-mediated asymmetric reduction of δ-symmetric bicyclic diketones 2a-c afforded the optical active ketols 3a-d in excellent enantioselectivity. Especially, ketol (+)-3b was the chiral intermediate for the total syntheses of (-)-cantabrenonic acids. Furthermore, usefulness of (+)-3b as a chiral bicyclic synthon was revealed by the short transformation of the ketol to the chiral intermediate (+)-4 in (+)-capnellenols syntheses (Scheme 5). 2. PPL-mediated asymmetric demethoxycarbonylation of achiral tetraester 9 obtained by Weiss reaction afforded the chiral triester (+)-10 in 98.3 %ee. The chiral triester was selectively demethoxycarbonylated to prepare chiral C_2-symmetry diester (+)-11. On the other hand, lipase AY-mediated asymmetric demethoxycarbonylation of achiral tetraester 9 directly afforded the chiral C_2-symmetry diester (-)-11 (100 %ee), having opposite chirality compared to the reaction with PPL. The results of lipase-mediated asymmetric transformation of achiral tetraester 9 are shown in Table 1. The chiral diesters (+)- and (-)-11 were very useful as chiral C_2-symmetry synthons for the total syntheses of (+)-carbacyclin, (-)-isoiridomyrmecin, (-)-ajmalicine (Scheme 7, 8, and 9).
  • パン酵母を用いるσ‐対称[3.3.0]Octane類の不斉変換反応, 井上武久, 細見光一, 北川豊, 野出学, 日本薬学会年会要旨集, 113th, Pt 2, 108,   1993 03 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902117632021280
  • 不斉ニトロオレフィン化反応の改良, 井上武久, 細見光一, 黒崎竜一, 野出学, 冨士薫, 日本薬学会年会要旨集, 113th, Pt 2, 127,   1993 03 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902142111192643
  • 光学活性三環性セキステルペン類全合成のための重要中間体の不斉合成研究, 井上武久, 細見光一, 野出学, 香料・テルペンおよび精油化学に関する討論会講演要旨集, 36th, 324, 326,   1992 10 , https://jglobal.jst.go.jp/detail?JGLOBAL_ID=200902071904440554
  • Inverse association between digoxin and cancers derived from real world data, Satoshi Yokoyama, Yasuhiro Sugimoto, Chihiro Nakagawa, Kouichi Hosomi, Mitsutaka Takada, PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 28, 199, 199,   2019 08 , Refereed